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Major Depressive Disorder (MDD) is a complex multifactorial disorder, which would lead 
to disability. Environmental and genetic factors are involved in MDD etiology. The aim of this 
project was to identify loci modifying age at onset (AAO) of MDD using survival models after 
adjusting for Childhood Sexual Abuse (CSA). To achieve this aim, a dataset was made available 
by the China Oxford and VCU Experimental Research on Genetic Epidemiology (CONVERGE) 
consortium. The study population had 5,220 controls and 5,282 cases with MDD. We performed 
two univariate association analyses using Cox Proportional Hazard (Cox PH) models. These two 
are Full Sample (FS), cases and controls, and only the Case Cohort (CC). No genome-wide 
significant associations were found in univariate analyses. Subsequent gene set enrichment 
analysis showed that there were significant enrichments in neurological Gene Ontology terms and 
some novel non-neural pathways. These findings may allow us to better understand MDD 
pathology. 
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1. Introduction
Major depressive disorder (MDD) (OMIM #608516) has lifetime prevalence in the range 
of 1-16.7% (Kessler & Bromet, 2013). It is also much more common in females than males and 
mean of age at onset (AAO) ranges from approximately 24 to 34 (Weissman et al., 1996). 
Psychiatric disorders, including MDD, have underlying genetic factors that modulate the risk for 
these disorders. A meta-analysis of twin studies showed that the heritability of major depression 
is 37% (Sullivan, Neale, & Kendler, 2000), which suggests that i) genetic factors are involved in 
MDD etiology and ii) there are also non-genetic risk factors for depression. In a twin study on 
Swedish twin sample, early AAO of MDD is significantly associated with increased liability to 
MD (Kendler, Gatz, Gardner, & Pedersen, 2005). 
Early medical intervention or lifestyle changes may ameliorate the prognosis of major 
depression. For this reason, prognostic markers are crucial for preventing exacerbations in patients 
developing depression. A single highly penetrant candidate risk locus has not been reported yet 
for MDD so this supports the common disease common variant hypothesis. On the other hand, 
Genome-wide association studies (GWAS) aim to identify numerous common variants that 
contribute to genetic liability to disease. Finding genome wide significant genetic loci would 
indicate possible biological mechanisms, which could be a potential target for drug design or 
prognostic marker for the disorder. 
The aim of this study was to uncover genetic modifiers that affect the MDD AAO in the 
entire sample or only within cases. Therefore, we conducted a genome wide survival analysis 
which tests for an association between CONVERGE genotypes and survival to onset of MDD 
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among 10,502 Han Chinese female participants. The association tests were performed using Cox 
Proportional Hazard (Cox PH) survival regressions.  
2. Background Information 
2.1. Depression Definition  
 The mood disorders, which include depression, have been known since ancient times. 
The classification of depression as a mental illness goes back to the description of melancholy by 
Hippocrates (460-377 BC). Major depression, a common chronic recurrent disorder, affects all 
social segments of the population. Major Depressive Disorder (MDD) (OMIM # 608516) is a 
common psychiatric disorder that is characterized by persistent depressed mood, reduced interests; 
lessened cognitive function, and/or vegetative symptoms like abnormal sleep or appetite, change 
in activity, lack of self-worth, suicidal thought and fatigue or loss of energy (Otte et al., 2016). To 
be diagnosed as MDD by DSM5 (American Psychiatric Association, 2013) out of these symptoms 
at least five or more should manifest in two-week period almost daily. Also, one of the symptoms 
has to be either depressed mood or reduced interest.  
 MDD is also an important public health problem due to the loss of ability to do work. 
The quality of life deteriorates in many ways as depression symptoms become more prominent. In 
particular, the worsening in social functioning can be more pronounced than in many other 
physical illnesses (Hirschfeld et al., 2000). The prevalence of MDD, the negative effects on both 
the individual and the community level, and the burden of this disorder, point to depression being 
an important public health problem and financial burden to the health care system.  
2.2. Epidemiology 
 Depression is one of the common psychiatric disorders. Studies on the epidemiology of 
depression have resulted in different rates of prevalence in different populations. Lifetime 
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prevalence of MDD differs from one country to another ranging from 1% to 16.9% (Kessler & 
Bromet, 2013). In China, the 12 month prevalence of MDD is estimated to be 2.3% and life time 
prevalence is 3.3% (Gu et al., 2013). In another study of 6,694 people, whose age range 18-96 
years old, the monthly prevalence of depression was 5.2% in states of California and New York in 
U.S. It has been reported that depression is seen at a higher rate in women and increases towards 
the middle of life (Ohayon, 2007). 
2.3. Etiology 
The etiology of MDD have been investigated for decades. Neurotransmitter systems play 
a crucial role in the etiology. With the start of use of monoamine oxidase inhibitor and tricyclic 
antidepressant (TSA) as a medical intervention to treat psychiatric disorders, "Monoamine 
Hypothesis" (Schildkraut, 1965) was introduced. Then, numerous studies were conducted on mood 
disorders, etiopathogenesis of depression, and neurotransmitters.  
The monoamine hypothesis suggests that the reduction in the function and deficiency of 
one of the three biogenic amines (serotonin, noradrenalin, and dopamine) or the increase in the 
number and sensitivity of its receptors is the underlying biological mechanism of depression. This 
hypothesis at first explained the cause of the depression in relation with the full or partial failure 
of noradrenalin receptor system, especially in functionally important noradrenalin receptor sites.  
The role of serotonin in depression has been extensively studied area of research. The 
"Serotonin/Indolamine Hypothesis" proposed that depressive disorders are a consequence of 
decreased serotonin levels in the brain (Racagni & Brunello, 1999; Stahl, 1998). There are also 
studies on symptoms of depression associated with reduced serotonin synthesis in the brain due to 
the lack of tryptophan (Neumeister et al., 2004).  
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 The underlying physiological decrease in dopamine (DA) signaling may result either 
from a reduction in release from the anterior synaptic neurons, or from impaired signal 
transduction due to changes in the number of receptors, function or altered signal processing 
among cells (Dunlop & Nemeroff, 2007). A study measured the level of 
major catecholamine metabolite, produced by the monoamine oxidase and catechol-O-methyl 
transferase on dopamine, (HVA) in internal jugular vein. Findings pointed out that decrease in 
HVA concentration correlated with the increase in depression severity in the patients’ with 
treatment-refractory depression (Lambert, Johansson, Agren, & Friberg, 2000).   
 As a result, there are supporting evidences of Monoamine Hypothesis such that serotonin 
and dopamine play a role in biology of depression. 
 
 
 
 
 
 
 
 
 
Figure.1 Etiology of MDD. 
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There is not any single mechanism that explaining the etiology of MDD (Fig.1). Stress 
plays a major role in etiology of MDD, specifically if encountered at earlier stages of life. A  
stressful event could trigger the Hypothalamic-Pituitary-Adrenal axis releasing corticosteroids (de 
Kloet, Joels, & Holsboer, 2005). Inflammation affects the HPA axis by increasing its activity 
(Besedovsky, del Rey, Sorkin, & Dinarello, 1986) The increase in activity leads to change in 
central nervous system hippocampal structure and function (Brown, Rush, & McEwen, 1999). 
Decrease in hippocampal neurogenesis could weaken the healthy response to stress (Santarelli et 
al., 2003). Lowered volume in hippocampus region also has a role in MDD etiology (Otte et al., 
2016).   
MDD is a complex disorder having both genetic and environmental components in its 
etiology. Two of the major environmental contributions come from the childhood adversity and 
stressful life events. As for the genetic component, twin studies indicated there is a heritability 
estimate of 37% for MDD (Sullivan et al., 2000). This suggests genetic factors are involved in 
etiology of MDD. Neurogenesis, HPA axis and inflammation affecting the HPA axis may also 
play a role due to their regulation of stress response.  
2.4. Risk Factors 
 
 
 
 
 
 
Figure.2 Risk Factors for MDD 
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There are various risk factors involve in MDD etiology. Among these, two broad categories 
are the genetic and environmental risk factors (Fig.2). 
2.4.1. Environmental risk factors in MDD 
Various studies have shown that being a woman, having a low level of education, genetic 
factors, the presence of a depressive personality, stressful life events, lack of close relationship, 
physical illness leading to loss of power and mental disorders are major risk factors for major 
depression (Swindle, Cronkite, & Moos, 1998). Being between the ages of 18-44, single, not 
working and having a low socioeconomic status are other risk factors for depression (Anthony & 
Petronis, 1991; Bruce, Takeuchi, & Leaf, 1991).  
For females, the rate of depression is found to be higher in separated and divorced than in 
married ones (Weissman et al., 1996). The effect of these risk factors differs depending on the 
severity of depression. For instance, biological susceptibility plays a more important role in severe 
cases of depression, while the role of environmental factors is more substantial in non-familial 
types of depression (Farmer, 1996).  
One of the important environmental risk factors for MDD is CSA. Research shows that 
CSA is an indication of earlier AAO of depression (Gladstone et al., 2004). A report on MDD in 
Chinese women indicated that CSA is associated with the recurrent MDD (Chen et al., 2014). 
2.4.2. Genetic risk factors in MDD 
At first, psychiatric genetics tried to uncover the genetic factors affecting the liability of 
individuals to disease via family, twin and adoption studies. A meta-analysis of twin studies 
(Sullivan et al., 2000) estimated the heritability of MDD at 37%, which suggests that genetic 
factors are involved in  etiology of MDD. It is more likely that heritable forms of depression are 
diagnosed especially early in life, and tend to be recurrent. It is thought that the heritability of 
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depression is not derived from a single locus, but from the joint effects of multiple genetic loci. 
Such hypothesis is supported by children of depressed patients being three to four times more 
likely to develop MDD (Sullivan et al., 2000; Weissman et al., 2006). Familial risk for MDD 
includes genetic factors, family environment, and specific risk factors of an individual (Avenevoli 
& Merikangas, 2006). 
2.4.2.1. Candidate gene approaches 
The serotonin transporter gene, SLC6A4, (Goldman, Glei, Lin, & Weinstein, 2010) is one 
of the most studied genes in major depressive disorder (Levinson, 2006). The reason for the focus 
of research on this gene is that there are 2 different (long / Long and short / Short) genetic 
polymorphisms. The short allele decreases the transporter synthesis of serotonin. This decrease 
may slow down the adaptation of the serotonin neurons to the stimulus (Lesch et al., 1996). An 
association study reported that there is a significant association between antidepressant treatment 
response and A allele of rs7997012 in serotonin 2A receptor (5HTR2A) gene (McMahon et al., 
2006). Catechol-o-methyl transferase (COMT) (Dopamine catabolism) gene have been studied to 
understand the genetics of MDD. In a multicenter European cohort, results pointed out that there 
is an association between the COMT Val/Val genotype and MDD (Massat et al., 2005). 
An association study on 300 depressed patients and 265 healthy controls showed that 
rs1386494 in TPH gene tryptophan hydroxylase 2 (TPH 2) (serotonin synthase) gene has 
statistically significant (Padj=0.012) association with MDD after adjusting for multiple testing 
correction (Zill et al., 2004). 
2.4.2.2. Genome-wide association studies 
There were two main developments in human genome research. The Human Genome 
Project and the International HapMap project, which allowed us to build a reference for the human 
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genome sequence. They also aimed to discover the human genome by identifying the genetic 
locations of about 25,000 genes. Two human genome drafts were published in 2001 (Lander et al., 
2001; Venter et al., 2001) and the completed human genome was published later (International 
Human Genome Sequencing, 2004). The International HapMap project aimed to catalog common 
human sequence similarities by publishing a genome-wide database of genomic sequences of 
individuals from different populations (International HapMap, 2005). 
One of the main goals of the HapMap project is to facilitate the identification of genetic 
variants that are associated with diseases under the common disease common variant hypothesis 
(Collins, Guyer, & Charkravarti, 1997; Gershon, Alliey-Rodriguez, & Liu, 2011; Lander, 1996; 
Pritchard & Cox, 2002). According to this hypothesis, most genetic variants leading to complex 
diseases should have minor allele frequencies greater than 5%. These genetic variants are risk 
factors or susceptibility variants to the disease. As a result of reduce in the cost of technologies, 
DNA microarrays allow us to assay hundreds of thousands of genetic variants at the same time. 
After the HapMap project, efforts focused on identifying ‘tag’ SNPs as representative of haplotype 
blocks. These efforts opened the door for effective and cost-efficient chip-based Genome Wide 
Association Studies (GWAS). Eventually, this method resulted in finding common variants 
associated with complex disorders. After the first GWAS was successfully performed (R. J. Klein 
et al., 2005), a growing number of GWAS studies have been conducted.  
The first large scale GWAS on 18,759 independent and unrelated European descent 
individuals (9,240 MDD cases and 9,519 healthy controls) did not uncover any replicable genome 
wide significant loci associated with MDD risk (Major Depressive Disorder Working Group of 
the Psychiatric et al., 2013). However, they found 15 genome wide significant SNPs in the cross-
disorder analyses (MDD-Bipolar disorder).  Subsequently, CONVERGE consortium reported 
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that two loci (LHPP and SIRT1) associated with MDD risk reached genome wide significance in 
a large Han Chinese cohort including only women (consortium, 2015). Another large GWAS in a 
European cohort found 15 independent loci associated with the risk of MDD (Hyde et al., 2016). 
However, they could not reproduce the CONVERGE results.  
There are still gaps in the genetic architecture of MDD. For instance, gene-environment 
interaction analysis is still in its infancy. Similarly, the analysis of rare and structural variations 
would be the focus for the next MDD studies. 
2.4.2.3 Genome-wide survival analysis 
Genome wide studies allow us to investigate the whole genome. This approach showed 
bore some success when applied to psychiatric disorders, e.g. CONVERGE MDD study 
(consortium, 2015). However, another interesting research focus of MDD might be to uncover 
genetic variants that increase or decrease AAO, i.e. AAO modifiers.  
The study of AAO modifiers for a complex genetic disorder is achieved by conducting a 
Genome-wide Survival analysis (GWSA). However, their application to complex disorders such 
as psychiatric disorders is rather scant. In one of them, a study on alcohol dependence uncovered 
three loci significantly associated with the AAO of Alcohol dependence (Kapoor et al., 2014).  
2.5 Survival analysis 
Survival analysis is a statistical method of research that deals with the time it takes for a 
subject to reach the event of interest. Today, survival analysis is an important research method for 
various scientific fields to investigate the time until the breakdown of equipment, the occurrence 
of a disease, or the time it takes until an earthquake occurs (Cox, 1972). In survival analysis, the 
length of interval to failure is treated as a dependent variable.  
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2.5.1. Censoring  
The concept of censoring is what sets survival analysis apart from other statistical methods. 
The censored observation is an unfinished observation and provides some information about the 
timing of the failure to occur. This means that although a unit or an individual has been under 
observation for a certain period, it has not failed during this interval. In this case, the time of the 
event is beyond the observed censoring time, and it may or may not occur later.  
 
 
 
 
  Figure.3 Possible censoring types. 
For instance, some of the patients observed may still be living at the end of the study. Also, 
an individual under observation cannot be studied due to dropping off from the study. If the time 
of failure is outside the observation period due to such reasons, it is denoted as a censored 
observation (Lee & Wang, 2003, p. 2). 
The concept of censoring is shown graphically in Fig.3. Here, I index (I = 1, 2, ...) refers to the 
time when events occur (Lee & Wang, 2003, pp. 3-4). 
I1 = the event has an end time outside the observation period (i.e. right-censored observation). 
I2 = event has an actual start time outside of the observation period (i.e. left-censored observation). 
I3 = event has started and ended at a time outside of the observation period. 
I4 = the event has known start and finish time.  
In this study, there were only right-censored individual observations in the phenotype dataset. 
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2.5.2. Cox Proportional Hazards Model (Cox PH) 
One of the frequently used models in survival analysis is the Cox proportional hazard (PH) 
model (Cox, 1972). Although the model assumes proportional hazards, there is no definite form 
of probability distribution for survival times. For this reason, the Cox PH model is described as a 
semi-parametric model. 𝑋1, 𝑋2, 𝑋3, … , 𝑋𝑛 are explanatory variables and 𝑥1, 𝑥2, 𝑥3, … , 𝑥𝑛 are the 
values of these variables. In the Cox PH model, the set of values of the explanatory variables is 
denoted by x vector, (𝑥1, 𝑥2, 𝑥3, … , 𝑥𝑛). The baseline hazard function is ℎ0(𝑡). Cox proportional 
hazards model for the 𝑖𝑡ℎ individual (J. P. Klein & Moeschberger, 2003, pp. 244-245), 
 ℎ𝑖(𝑡) = ℎ0(𝑡)exp (𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑖 + ⋯ + 𝛽𝑛𝑥𝑛𝑖) (1) 
2.5.3. Proportional Hazards Hypothesis 
 The proportional hazard assumption implies that the hazard ratio is constant over time. In 
the survival analysis, the hazard ratio is defined as the effect of the explanatory variable on the risk 
of the event involved. The hazard ratio, which is the vector of explanatory variables of two groups 
𝑥 = (𝑥1, 𝑥2, … , 𝑥𝑛) and ?̂? = (?̂?1, ?̂?2, … , ?̂?𝑛)(J. P. Klein & Moeschberger, 2003, pp. 244-245). 
 𝜃 =
ℎ̂0(𝑡)𝑒
(∑ ?̂?𝑗𝑥𝑗
∗𝑛
𝑗=1 )
ℎ̂0(𝑡)𝑒
(∑ ?̂?𝑗𝑥𝑗
𝑛
𝑗=1 )
=
𝑒∑ ?̂?𝑗𝑥𝑗
∗𝑛
𝑗=1
𝑒∑ ?̂?𝑗𝑥𝑗
𝑛
𝑗=1
= 𝑒
(∑ ?̂?𝑗
𝑛
𝑗=1 (𝑥𝑗
∗−𝑥𝑗))
 (2) 
 The  parameter is the natural logarithm of the hazard ratio. Equation 2 does not include 
the base hazard ratio ℎ̂0(𝑡) (J. P. Klein & Moeschberger, 2003, pp. 244-245). In other words, when 
values for x* and x are specified, the value of the exponential term is fixed for the hazard ratio 
estimation, meaning that it is not time dependent. If this is denoted by constant θ, the hazard ratio 
can be written as given in Equation 3: 
 𝜃 =
ℎ̂(𝑡,  𝑥∗)
ℎ̂(𝑡, 𝑥)
 (3) 
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Equation 3 is a mathematical expression of the proportional hazard assumption. Another 
mathematical expression of proportional hazard assumption; 𝜃 ℎ̂ (t, x) = ℎ̂ (t, x*). Here, 𝜃 is called 
the proportionality constant and it is time independent (J. P. Klein & Moeschberger, 2003, p. 245). 
To check the proportionality assumption researchers commonly plot the survival curves using the 
Kaplan Meier estimates for each group (Persson, 2002, pp. 26-27). The use of the classical Cox 
proportional hazards model is not appropriate if the fundamental assumption of proportional 
hazards is grossly violated.  
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Figure.4 Work Flow of GWAS and its processing. 
2. Methods 
There were some major steps in an overall workflow of a GWAS as simplified in a 
schematic below (Fig.4). The scope of this study is also pointed out as thesis project on this 
workflow. Genome wide association genotype data was provided by the CONVERGE consortium 
(consortium, 2015). We are using a QC-ed subset of this dataset including genotype data and 
phenotype data of 10,502 individuals, e.g. age at examination, age at onset of MDD and with CSA.  
 
  
  
   
 
 
 
  
 
 
 
3.1. Study population 
All participants are female and of Han Chinese descent, who recruited from 58 different 
mental health clinics. Controls were recruited from patients coming to the same clinics for lesser 
surgical operations. The case group consisted of 5,282 female participants diagnosed with MDD 
and the control group consisted of 5,220 females with no history of MDD. The mean age at 
interview for the control group was 47.66 with a standard deviation (std) of 5.61 and the age at 
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Figure.5 Histogram of age at interview distribution within the control group (left, n=5,220) and 
age at onset (AAO) distribution within the case group (right, n=5,282) 
onset is 35.75 with std of 9.36 for the case group (Fig.5). There were 412 individuals in the case 
ohort with AAO < 18 years. These cases were excluded from the final statistical analysis.  
 
 
 
 
 
 
 
 
   
  
The clinical diagnoses of MDD were according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) criteria. The case group had several exclusionary criteria, such as 
having bipolar disorder, psychosis or mental retardation. All required permissions were granted 
from participating hospitals’ ethics review committees. Details of the participation, the interview 
with individuals included into the case group and recruitment criteria were explained previously 
in a CONVERGE report (consortium, 2015).   
3.2. Genotyping 
In this study, genotyping experiment used genomic and mitochondrial DNA extracted from the 
saliva samples of each participant. The genetic data was low pass whole-genome sequencing data 
(low coverage, the average at around 1.7x) that was carried out on Illumina Hiseq. This allowed 
us to assay all variants either inside the protein coding or noncoding genomic regions. Alignment 
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Figure.6 Distribution of Minor Allele Frequencies (MAF) of SNPs. 
of sequence reads to a reference human genome (GRCh37.p5) was completed with Stampy 
(v1.0.17) (Lunter & Goodson, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After filtering out SNPs with MAF < 0.01 (Fig. 6), out of 9,708,891 SNPs, 6,755,406 SNPs 
were selected for the Cox PH regression analysis.  
The genotype data (single nucleotide variant, SNVs) had already been imputed and 
processed through stringent quality control (QC) processes. All the steps explained in this section 
were carried out by the CONVERGE consortium. The details of these procedures is described in 
the previously published research article (Cai et al., 2017).  
Variant discovery and genotyping has been processed with GATK’s Unified Genotyper (v2.7-2). 
1000 genomes Phase 1 East Asian sample was used as the reference panel for variant calls. SNVs 
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were named based on the SNV database version 137 (dbSNP v137) on NCBI. For genotype 
imputation, BEAGLE was used (Cai et al., 2017). Genotype data included in this study has 99% 
called SNVs (consortium, 2015). For all called SNVs, p-value for violation of Hardy-Weinberg 
equilibrium (HWE) is P > 10-7, minor allele frequencies (MAF) > 10-3 and information score > 
0.3. For the statistical analysis, only 6,748,514 SNPs were included in the final two statistical 
models (FS analysis and CC analysis) described below. 
3.3. Statistical model 
We used a Cox proportional hazard (PH) regression model to investigate possible 
significant associations between AAO of MDD and genotype of SNVs (Cox, 1972). In this study, 
the Cox PH analyses were run on the R statistical program using the “survival” library (Therneau 
et al., 2000). For depression, the survival object of the Cox regression function defines the time to 
event, which in this case is MDD AAO. The control group was right censored, i.e. the disease 
phenotype has not been observed in those healthy individuals at the time of medical examination. 
The ancestral PCA plot was computed using all 10,502 subjects. Principal Component 1 
(PC1) and Principal Component 2 (PC2) explained the geographical distribution of the subjects 
(Fig.7). Thus, these two PCs were included in the survival regression model to account for 
population stratification.  
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Figure.7 Ancestral Principal Component Analysis (PCA). Red and grey color filled circles 
represent cases and controls, respectively. 
We performed two different analyses. The first one was in Full Sample (FS) and the 
second was in Case Cohort (CC) only. The statistical model for the analyses contains genotype 
as predictor and the first two principal components and CSA as covariates. I.e. 
ℎ𝑖(𝑡, 𝑋) =  ℎ0(𝑡)𝑒𝑥𝑝(𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + 𝛽4𝑋4 ) 
ℎ(𝑡|𝑥) =  ℎ0𝑒
𝛽1𝑋1+𝑋2𝛽2+𝛽3𝑋3+𝛽4𝑋4 
𝑋1―› Genotype vector 𝑋2―› 1st Ancestral Principal Component  
𝑋3―› 2nd Ancestral Principal Component    𝑋4―› CSA vector 
 h0 → Baseline hazard (no assumption). 
We chose Bonferroni as the multiple testing correction method for p-values from the 
genetic association analyses. An example of Cox PH regression model for FS analysis in R is 
shown in Fig.8. Highlighted with yellow rectangle is the R function in the survival library. Marked 
in i) red is the hazard ratios and ii) blue is the significant p-value. Also highlighted in Fig.8, “Surv” 
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Figure.8 Cox regression model in R (“survival” library). 
(survival) function in R survival library was the object specific to survival analysis. This function 
generates the Survival object in R function. Survival object includes individual observations of the 
time to event either being right censored or not. In this case, observations (AAO) in the case group 
are not censored whereas observations (age at interview) in control group is right-censored. The R 
script used for the of the Cox PH regression analysis can be found in the Appendices.  
 
. 
 
 
 
 
 
 
 
 
To empirically test the significant p-values, we conducted a permutation tests on four top 
SNPs (Table.5 in the Appendices), which all have MAF < 1 %. These SNPs were tested with at 
least 5x105 permutations.  
3.4. Gene set enrichment analysis 
Most GWAS analyses end up with a large number of loci having numerous moderate but 
none/few genome wide significant association signals.  For this reason, a possible approach to 
analyze these findings is to conduct an aggregate analysis. Gene set enrichment analysis is one of  
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Figure.9 Gene enrichment and path analysis workflow. 
Figure.10 Schematic of gene regions. 
the most well-known such methods.  It allows us to aggregate information over numerous loci in 
biological pathways. 
 
 
 
 
 
 
 
 
 
To achieve this, first step was setting a SNP prioritization threshold of genetic association 
significance to select SNPs (Fig.9). So, after the selection of the moderately significant Single 
Nucleotide Variations (SNVs) based on an a priori significance threshold (P < 10-3). They were 
mapped to (sometimes multiple) genes (Fig.10). A variant was deemed as mapped to a gene when 
it was located within 50 kb of coding sequences of the gene. 
 
 
 
 
 
For this purpose, g:SNPense was used for SNP mapping to genes (Fig.11). This SNP 
mapping tool is an online SNP IDs converting application (http://biit.cs.ut.ee/gsnpense). It accepts 
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Figure.11 SNV mapping to genes (g:SNPense). 
a list of at most 4,000 rs IDs as a query. This list of rs IDs were converted into a gene list. 
g:SNPense mapped all SNPs residing within the 50kb upstream and downstream region of the 
coding sequence of a gene, including 3` and 5`-UTR regions mapped to a single or multiple genes 
(Fig.10). This allowed us to form a gene list to be used as a query for gene set enrichment analyses.  
 
 
 
 
 
 
 
 
In order to test the list of genes for enrichment in any biological pathways or curated gene 
sets, an online tool called Gene Group Functional Profiling (g:GOSt) version r1730_e88_eg35 
(Ensembl 88, Ensembl Genomes 35 (rev 1730, build date 2017-05-18)) was used for gene set 
enrichment analysis (Fig.12) (Reimand et al., 2016). If needed, there are older versions of g:GOSt 
in the archive tab on the g:Profiler website. 
All g:GOSt queries had the same options selected as shown in Fig.12. Selected SNPs from 
FS analysis mapped to 998 genes. For the CC analysis, the query had 1,147 genes. The two gene 
lists are in the Appendices. From the options list of g:GOSt, for gene set enrichment analysis, there 
were only GO (Gene Ontology) terms and two biological pathways (KEGG and Reactome) 
selected.  
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Among other options, three can significantly affect the results of the gene enrichment 
analysis. These options were ordered query option, including Electronic GO annotations and 
multiple testing adjustment method of p-values in the gene enrichment analysis. The key point in 
the query was the selection of the ordered (ranked) query option. This allowed us to perform a test 
for enrichment based on an ordered query of the descending statistical significance of genetic 
associations. The selected options for the gene set enrichment analysis were the same as in Fig.12. 
The ambiguous gene identifiers (IDs) were resolved manually. By default, g:GOSt searches query 
gene IDs in 116 different databases. In queries, gene IDs were either HGNC (HUGO Gene 
Nomenclature Committee) gene symbol or Ensemble gene ID. Duplicates of gene IDs were 
automatically discarded by g:GOSt. 
The test for significance of the pathway enrichment in the query gene list is based on a 
hypergeometric test. In order to show enrichment results separately for each category (source) of 
Figure.12 Gene enrichment analysis (g:GOSt). 
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GO term group and pathway gene set, we queried the gene lists once at a time selecting only one 
GO term category or the pathway gene set as the query option on the g:GOSt option panel.  
g:GOSt can provide adjusted p-values for multiple testing based on three options, which 
are Bonferroni’s, Benjamini–Hochberg False Discovery Rate (FDR) (Benjamini, Drai, Elmer, 
Kafkafi, & Golani, 2001) and a modified method (g:SCS method) developed by the g:Profiler 
research group (Reimand, Kull, Peterson, Hansen, & Vilo, 2007). For the gene set enrichment 
analyses, Bonferroni’s method was method to adjust enrichment p-values for multiple testing.  
For validation purposes, an additional web based tool from Max Planck Institute called 
ConsensusPathDB  (Herwig, Hardt, Lienhard, & Kamburov, 2016) that shows the raw 
(unadjusted) p-values along only with their FDR adjustment. The significance for the enrichment 
analysis was set as q-value < 0.05. Thus, only for the purpose of this comparison, the change in 
options panel were deselection of the ordered query option and switching the multiple testing 
method from Bonferroni to FDR in g:GOSt. 
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Figure.13 Quantile-quantile plot of p-values from summary statistics 
of AS analysis. 
 
4. Results 
Two different Cox PH analyses, denoted Full Sample (FS) and Case Cohort (CC), were 
implemented in this study to uncover modifier SNPs. Survival GWAS did not yield any genome 
wide significant SNPs, however, there seemed to be several suggestive SNVs (p-value < 5x10-5) 
associated with the AAO of the MDD.  
4.1. Genome wide survival analysis results 
4.1.1 All Sample analysis results 
Quantile-quantile plot (Q-Q plot) showed (Fig.13) some departures from the null 
expectation (shaded area shows the 95 % confidence interval). The early deviation from the 
diagonal line points out that the p-values did not follow the expected null distribution. (Genomic 
inflation was estimated to be 1.075) This departure was either due to enrichment or to liberal tests. 
However, given that the permutations p-values were much larger than survival regression p-values, 
it is likely that the departure was due to liberal survival tests.  
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Table.1 30 most significant SNVs in FS analysis. 
CHR SNV BP MAF Hazard Ratio (HR) Z score P (unadjusted) 
10 rs11245287 126246537 0.261 0.880 -5.286 1.25x10-7 
10 rs35841851 126236419 0.296 0.885 -5.242 1.59x10-7 
10 rs11245283 126236663 0.297 0.886 -5.214 1.85x10-7 
10 rs35936514 126244970 0.260 0.882 -5.203 1.96x10-7 
10 rs12258489 126245297 0.260 0.883 -5.167 2.38x10-7 
1 rs74359973 187629589 0.011 1.568 5.026 5.01x10-7 
6 rs55800092 4386107 0.150 0.861 -5.015 5.30x10-7 
10 rs12262706 126247468 0.292 0.890 -5.003 5.64x10-7 
6 rs17138114 4379511 0.151 0.862 -4.973 6.61x10-7 
6 rs7747061 4381445 0.151 0.862 -4.973 6.61x10-7 
6 rs56222106 4374034 0.150 0.863 -4.935 8.02x10-7 
6 rs75592374 4374582 0.150 0.863 -4.935 8.02x10-7 
6 rs1888325 4374751 0.150 0.863 -4.935 8.02x10-7 
6 rs78823440 4375064 0.150 0.863 -4.935 8.02x10-7 
6 rs1034115 4391428 0.150 0.864 -4.910 9.12x10-7 
6 rs170950 4391144 0.150 0.864 -4.903 9.44x10-7 
6 rs77648291 4375421 0.145 0.861 -4.886 1.03x10-6 
23 rs140957023 140958072 0.017 1.498 4.874 1.10x10-6 
1 rs181909501 48949127 0.020 6.235 4.842 1.28x10-6 
1 rs78146918 187610780 0.011 1.538 4.839 1.30x10-6 
13 rs116500056 107657974 0.017 1.413 4.769 1.86x10-6 
13 rs16969523 107658220 0.017 1.412 4.756 1.97x10-6 
13 rs35061615 107658285 0.017 1.412 4.756 1.97x10-6 
13 rs35932768 107658655 0.017 1.412 4.756 1.97x10-6 
13 rs61967003 107659212 0.017 1.412 4.756 1.97x10-6 
13 rs16969540 107662658 0.017 1.412 4.756 1.97x10-6 
13 rs12861527 107663978 0.017 1.412 4.756 1.97x10-6 
13 rs7990181 107667344 0.017 1.412 4.756 1.97x10-6 
10 rs80309727 107667344 0.017 1.104 4.746 2.08x10-6 
8 rs59341197 23461233 0.278 0.895 -4.742 2.11x10-6 
BP: base pair, SNV: Single Nucleotide Variant, P: p-value, MAF: Minor Allele frequency, CHR: Chromosome 
 
 The 30 most significant SNVs (Table 1) were all suggestive (P < 5x10-5) genome wide 
significant associations. These SNVs are common variants and have MAF greater than 1 %, 
whereas SNVs on chromosome 13, 1 and 23 have MAFs that are close to 1%. The most significant 
SNV association was on Chromosome 10 in LHPP locus. This locus was also reported as having 
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genome wide significant association signal for SNVs inside an LHPP intron (consortium, 2015). 
Another point is that SNVs on LHPP with HR < 1 implicates the tested allele as being protective. 
Table.2 Genes located near suggestive SNPs in FS analysis. 
SNP ID Gene   
Gene 
region 
P value MAF Gene Chr 
Gene 
Association
* 
rs11245287 LHPP intron 1.247x10-7 0.261 
phospholysine 
phosphohistidine 
inorganic pyrophosphate 
phosphatase 
10q26.13 
cholesterol, 
anticoagulant 
rs140957023 MAGEC3 intron 1.096x10-6 0.017 
 MAGE family member 
C3 
Xq27.2 NA 
rs78146918 
ERVMER6
1-1 
intron 1.305x10-6 0.011 
endogenous retrovirus 
group MER61 member 1 
1q31.1 NA 
rs80309727 RNU6-523P intron 2.075x10-6 0.453 
RNA, U6 small nuclear 
523, pseudogene 
10q21.3 NA 
rs59341197 RNU4-71P upstream 2.114x10-6 0.278 
RNA, U4 small nuclear 
71, pseudogene 
8p21.2 NA 
rs192525648 CCL17 intron 1.305x10-6 0.011 
C-C motif chemokine 
ligand 17  
16q21 NA 
rs118149296 ADAM23 intron 2.289x10-6 0.018 
ADAM metallopeptidase 
domain 23 
2q33.3 NA 
rs56197202 RNU4-71P intron 2.327x10-6 0.273 
coiled-coil domain 
containing 88C 
14q32.11
-q32.12 
Dehydroepia
ndrosterone, 
Albuminuria 
*NCBI Phenotype-genotype integrator NHGRI or dbGAP p-value<5x10-5 Chr: Chromosome MAF: Minor Allele Frequency 
 
The majority of the most significant variants that were mapped to genes were in/near genes 
that have no known association with any disease phenotype and have low MAF (~1%) (Table.2). 
Exceptions are rs11245287 and rs56197202, which are common variants with MAF around 26%. 
These two common variants are located in introns of LHPP and RNU4-71P respectively. The SNP 
in LHPP was the most significant one.  
According to the NCBI Phenotype-genotype integrator, https://www-ncbi-nlm-
nihgov.proxy.library.vcu.edu/gap/phegeni?tab=1&gene=64077, rs4315021 variant in LHPP is 
associated with (p-value = 3.06 x 10-5) total cholesterol concentration in blood. This result 
particularly belongs to NHLBI Family Heart Study (dbGaP Study Accession: phs000221.v1.p1  
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Figure.14 Manhattan plot of − log10(𝑃) for FS analysis. The red horizontal line points out the 
genome wide significance threshold (P = 5x10-8) and the blue horizontal line signs the suggestive 
significance level of genetic association (P = 5x10-5). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
As mentioned before, for obtaining variant association statistics there were both case and 
control subjects included in the AS analysis (Fig.14). LocusZoom online tool generated regional 
association plots allow us to explore the loci showing suggestive genome-wide significant 
associations. (Fig. 15-18). LocusZoom used all analyzed SNVs residing within the locus and p-
values used as an input for regional association locus plotting (Pruim et al., 2010). To generate 
these plots, LD population was set to ashg19/1000 Genomes Nov 2014 ASN (East Asians). 
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Figure.16 Locus zoom for SIRT1. 
Figure.15 Locus zoom for LHPP. 
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Figure.17 Locus zoom for chr13:107,257,974−108,057,974. 
Figure.18 Locus zoom for chr6:3,986,107−4,786,107 bp. 
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Figure.19 Quantile-quantile plot for CC analysis. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2 Case Cohort analysis results 
CC analysis also showed some departure from null expectation (Fig.19). Genomic inflation 
was 𝜆 = 1.014. As shown in Fig.19, there was a deflation in the association p-values towards the 
right tail of the Q-Q plot, however, the top six significant SNV associations, were within the 95% 
confidence interval of the expected normal distribution. 
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Table.3 30 most significant SNVs from the CC analysis. 
 
The 30 most significant SNVs in CC analysis (Table.3) were all suggestive (P < 5x10-5) 
genome wide significant associations. The most significant SNV association was Chromosome 7  
rs690911 (P = 1.80x10-7, HR=1.264). This locus have two overlapping genes that are ZPBP and 
VWC2. 
 
CHR SNP BP MAF Hazard Ratio (HR) Z score P (unadjusted) 
7 rs690911 49939147 0.0562 1.264 5.219 1.80x10-7 
7 rs2366025 50080818 0.0563 1.264 5.200 1.99x10-7 
7 rs6944334 50018441 0.0560 1.264 5.200 1.9910-7 
7 rs692270 49892044 0.0576 1.257 5.132 2.86x10-7 
7 rs691417 49887533 0.0562 1.254 5.002 5.69x10-7 
3 rs151020965 11904509 0.0222 1.427 4.908 9.21x10-7 
21 rs74591900 32762165 0.0265 1.439 4.760 1.93x10-6 
7 rs72590997 52362582 0.1270 0.864 -4.712 2.45x10-6 
7 rs72590998 52362961 0.1270 0.864 -4.712 2.45x10-6 
7 rs72591000 52379298 0.1269 0.864 -4.712 2.45x10-6 
7 rs9642460 52384825 0.1271 0.864 -4.684 2.82x10-6 
16 rs77700579 81490144 0.0952 1.181 4.679 2.88x10-6 
7 rs7778784 50135200 0.0577 1.231 4.675 2.94x10-6 
12 rs11173011 40046408 0.2019 1.132 4.664 3.10x10-6 
6 rs36142524 101946461 0.0218 1.446 4.648 3.34x10-6 
7 rs2221656 50099404 0.0579 1.229 4.640 3.48x10-6 
14 rs1285804 91819984 0.0161 1.436 4.639 3.49x10-6 
14 rs1285806 91822382 0.0161 1.436 4.639 3.49x10-6 
14 rs1285807 91823106 0.0161 1.436 4.639 3.49x10-6 
14 rs1285811 91830078 0.0161 1.436 4.639 3.49x10-6 
12 rs7295237 71016832 0.1204 1.176 4.609 4.05x10-6 
2 rs4666290 30149295 0.2274 1.133 4.601 4.21x10-6 
7 rs79417164 50170934 0.0282 1.345 4.592 4.40x10-6 
12 rs75833894 86726432 0.0461 1.276 4.582 4.60x10-6 
2 rs13414785 30149187 0.2323 1.132 4.570 4.87x10-6 
14 rs1285768 91797825 0.0123 1.515 4.569 4.90x10-6 
5 rs2135026 155810433 0.1743 1.141 4.563 5.05x10-6 
12 rs7978510 40038294 0.2018 1.130 4.558 5.16x10-6 
9 rs1819343 117328001 0.3978        0.908 -4.543 5.55x10-6 
7 rs1483080 50045825 0.0641 1.208 4.533 5.82x10-6 
BP: Base Pair, SNV: Single Nucleotide Variant, P: p-value, MAF: Minor Allele Frequency, CHR: Chromosome 
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Table.4 SNVs mapped to genes in the CC analysis. 
SNP ID Gene   
Gene 
region 
MAF p-value Gene Chr 
Gene 
Association* 
rs690911 
ZPBP/ 
VWC2 
intron 0.056 1.796x10-7 
zona pellucida binding 
protein / von 
Willebrand factor C 
domain containing 2 
7p12.2 
NA/cholesterol, 
triglycerides, 
sleep, calcium, 
platelet 
aggregation 
rs151020965 FANCD2P2 intron 0.022 9.209 x10-7 
Fanconi anemia 
complementation 
group D2 pseudogene 
2 
3p25.2 NA 
rs74591900 TIAM1 intron 0.027 1.935 x10-6 
T-cell lymphoma 
invasion and 
metastasis 1 
21q22.11 
ALS, Hip,  
Neuroblastoma,  
coronary disease, 
 lipids 
rs77700579 CMIP intron 0.095 2.881 x10-6 
c-Maf inducing protein 
(plays a role in T-cell 
signaling pathway) 
16q23.2-
q23.3 
Adiponectin, 
 cholesterol, 
HDL,  
Type 2 Diabetes,  
Body height 
rs7778784 C7ORF72 upstream 0.058 2.938 x10-6 
chromosome 7 open 
reading frame 72 
7p12.2 
NA / SLE,  
Chrone disease,  
Hippocampus 
rs11173011 C12ORF40 intron 0.202 3.103 x10-6 
chromosome 12 open 
reading frame 40 
12q12 NA 
rs36142524 GRIK2 intron 0.022 3.344 x10-6 
kainate type subunit 
2ily tyrosine kinase 
6q16.3 
Body weight,  
Cholestrol,  
LDL, 
Lipoprotein,  
FSH, BMI 
rs1285804 CCDC88C intron 0.016 3.493 x10-6 
coiled-coil domain 
containing 88C 
14q32.11
-q32.12 
Insulin, insulin 
resistance,  
BMI 
*NCBI Phenotype-genotype integrator NHGRI or dbGAP p-value < 5x10-5 Chr: Chromosome MAF: Minor 
Allele Frequency 
 
 
Most of the significant variants in CC analysis are known to exhibit significant association 
with other disease phenotypes (Table.4). Most of these SNPs are rather rare (MAF < 10%) with 
the exception of rs11173011, which is a common variant with MAF = 26%. This common SNP 
resides in C12ORF40 (chromosome 7 open reading frame 40). NCBI Phenotype-genotype 
integrator indicates that there are significant associations between variants in C12ORF40 and 
Systemic Lupus Erythematosus (SLE), Crohn’s disease. 
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Figure.20 Manhattan plot of − log10(𝑃) from CC analysis. 
 
The most significant association signal was located in one of the introns of von Willebrand 
factor C domain containing 2 (VWC2). According to the NCBI Phenotype-genotype integrator, 
there is a significant gene association between variants in VWC2 loci and cholesterol, triglycerides, 
sleep, calcium and platelet aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC analysis yielded the best signal on chromosome 7, which is, however, only suggestive 
(Fig.20). Locus zoom plot (Fig.21) explored the SNVs, which are in Linkage Disequilibrium with 
the most significant SNV (rs690911) in the VWC2 loci, nearby the ZPBP and C7ORF72 loci.  
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Figure.21 Locus zoom for VWC2, ZPBP and C7ORF72. 
 
 
 
 
 
 
 
 
 
 
4.2 Gene Set Enrichment Results 
Gene set enrichment analysis results are shown in summary (Table.5) and in Fig.23 pertaining to 
the graphical outputs obtained from the g:GOSt (Fig.12). The remaining results are in Appendices. 
[The gene lists associated with the two analyses are in Appendices (Table.7 and Table.8).] 
In summary, Table.5 shows the top significant gene set enrichments of GO term categories and 
Pathway (KEGG and Reactome) gene sets in each gene list of two models. Most of the significant 
enrichments were found in Cellular Component and Biological Process GO categories. The most 
significant enrichment for FS analysis was cell periphery (GO:0071944, q = 3.23x10-5). The most 
significant enrichment for CC analysis was synapse (GO:0045202, q = 1.33x10-5). Neuronal 
system (REAC:112316) was significantly enriched in both analyses.  
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Table.5 Summary table of gene set enrichment results. 
M
o
d
el
 GO Term / 
Pathway ID 
GO Term 
category 
Term or 
Pathway name 
Gene 
set  
Gene 
list 
Genes 
Shared  
 
qB qFDR 
FS 
GO:0071944 
Cellular 
Component 
cell periphery 
5283 795 180 3.23x10-5 6.66x10-8 
GO:0044700 
Biological 
Process 
single organism 
signaling 
6263 396 110 9.47x10-4 9.63x10-7 
GO:0065008 
Biological 
Process 
regulation of 
biological quality 
3428 380 69 1.04x10-3 1.06x10-6 
GO:0097458 
Cellular 
Component 
neuron part 
5283 795 180 1.10x10-3 1.12x10-6 
GO:0045202 
Cellular 
Component 
synapse 
809 944 50 1.63x10-3 1.65x10-6 
GO:0055085 
Biological 
Process 
transmembrane 
transport 
1395 526 48 3.77x10-3 3.84x10-6 
REAC:112316 Reactome neuronal system 359 886 26 4.76x10-3 8.74x10-4 
KEGG: 05231 KEGG 
choline 
metabolism in 
cancer 
101 664 10 2.36x10-2 1.35x10-3 
CC 
GO:0045202 
Cellular 
Component 
synapse 
809 1049 60 1.33x10-5 1.98x10-8 
GO:0097458 
Cellular 
Component 
neuron part 
1322 1130 91 2.02x10-5 3.01x10-9 
GO:0120036 
Cellular 
Component 
plasma membrane 
bounded cell 
projection 
organization 
1323 1112 86 4.59x10-5 1.35x10-7 
GO:0007156 
Biological 
Process 
homophilic cell 
adhesion via 
plasma membrane 
adhesion 
molecules 
156 509 16 5.67x10-5 8.44x10-8 
GO:0016358 
Biological 
Process 
dendrite 
development 
203 1039 25 7.08x10-5 1.05x10-7 
KEGG:04724 KEGG 
glutamergic 
synapse 
114 855 14 2.82x10-4 8.46x10-6 
KEGG:04713 KEGG 
circardian 
entrainment 
96 855 13 2.33x10-4 6.98x10-6 
GO:0005509 
Molecular 
Function 
calcium ion 
binding 
701 477 30 5.38x10-3 8x10-6 
REAC:392154 Reactome 
Nitricoxide 
stimulates 
guanylate cyclase 
25 188 4 3.21x10-2 6.66x10-4 
REAC:112316 Reactome neuronal system 359 1078 27 5x10-2 1.04x10-3 
GO: Gene Ontology KEGG: Kyoto Encyclopedia of Genes and Genomes qB: Bonferroni adjusted p-value qFDR: Benjamini–
Hochberg False Discovery Rate adjusted p-value 
Effective domain size / FDR significance: KEGG: 7,168 / P = 3.36x10-3, REAC: 10,635 / P = 3.68x10-4, GO:18,971 / P =  
6.28x10-3 
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Figure.22 Functional gene annotation used in “Evidence code”. 
All queries had the same panel of options for the gene set enrichment analysis as shown in Fig.12. 
The graphical output is in a matrix form with color coded cells designating the kind of annotation 
of the gene. 
 
 
 
 
   
There are seventeen different annotations (Fig.22). These codes are called “Evidence 
code”, which are helpful to interpret the gene enrichment analysis results in terms of reliability. In 
brief, the experimentally verified red color-coded annotations are more reliable than the blue color- 
coded ones, electronically annotated by in silico analysis. 
The graphical outputs of g:GOSt FS enrichment analyses reveal significant GO terms and 
pathways (Fig. 23, and Fig.25-28 in Appendices). For instance, Fig.23 shows a portion of the 
graphical output of g:GOSt from the ranked query of the gene list FS analysis. This output was the 
result of the query gene list of FS gene enrichment analysis when only the Biological Process GO 
term was selected on the options panel. The rest of the query genes are not on the g:GOSt graphical 
output figures due to large horizontal dimension of the graphical output from g:GOSt. 
The most significant GO term among the Biological Process category (Fig. 23) was single 
organism signaling (GO:0044700, q = 9.47x10-4).  
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Figure.23 g:GOSt results for Biological Process GO terms in FS analysis. 
The following two top two significantly enriched GO terms were regulation of biological 
quality (GO:0065008, q = 1.04x10-3) and the transmembrane transport (GO:0055085, q = 3.77x10-
3). There were 1,395 genes in transmembrane transport GO term. The gene list query for this GO 
term consisted of 526 genes. Number of shared genes between the gene query list and the term 
gene set was 48 genes.  
4.3 Cross platform comparison of gene enrichment analysis results between 
ConsensuspathDB and g:Profiler. 
In order to assess the reliability of the g:Profiler platform, we used the same query gene list in 
another online gene set enrichment tool called Consensus Path DataBase (CPDB) from Max 
Planck Institute for Molecular Genetics. The slight difference between the results of the two 
platforms (Table.6) were mainly due to the number of genes recognized as the query genes and 
the number of genes by default in each GO term.  
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Table.6 A brief comparison of FS analysis enrichment results of the same queries between 
Consensus Path Database and g:Profiler. 
  g:Profiler/CPDB 
GO term ID GO term 
gene set 
size 
overlapping 
genes  
p-value 
(unadjusted) 
q-value  
GO:0048648 
Cell 
Development 
1907 / 1859 87 / 87 NA / 5.79x10-6 2.78x10-3/2.41x10-3 
GO:0044700 
 
single 
organism 
signaling 
 
6263 / 6201 237 / 227 NA / 1.47x10-5 3.53x10-4/7.18x10-4 
 
GO:0071944 
 
cell periphery 5283 / 5176 217 / 205 NA / 1.86x10-7 1.96x10-6/6.84x10-6 
GO:0097060 
 
synaptic 
membrane 
 
289 / 267 24 / 21 NA / 3.83x10-5 4.95x10-4/4.85x10-4 
GO: Gene Ontology q-value: Benjamini-Hochberg method for False discovery rate NA: 
Not applicable CPDB: Consensus Path DataBase  
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5. Discussion 
This study aimed to use whole genome survival regression to uncover genetic modifiers of 
MDD AAO. To achieve the aim, we employed two Cox PH analyses Full Sample (FS) and Case 
Cohort (CC) only.  These analyses used ancestry principal components (PCs) and child sexual 
abuse (CSA) as covariates. While there were no statistically significant univariate findings, 
aggregate analyses show enrichment in some of the expected places, e.g. neuronal and synaptic 
pathways. However, CC analysis revealed some interesting non-neuronal pathways that might 
provide avenues for future treatments. 
The most significant genetic association in all univariate analyses occurred in the intronic 
region of LHPP. Previously, in the CONVERGE consortium GWAS, this locus has been reported 
as having genome wide significant SNP (consortium, 2015). The reason for getting similar genetic 
associations in the FS analysis would be that the FS analysis used the same genotype data and 
almost the same cohort. Maybe not unexpectedly, because using only cases, Cox PH CC analysis 
yielded rather different results from FS analysis.  
 The reason for not finding any genome wide significant loci in both analyses could be due 
to lack of power for this analysis. Similar to most initial studies of psychiatric disorders, an increase 
in the study sample size would uncover loci that have fallen just below the genome wide significant 
threshold in current study. (For our two analyses (FS and CC) we had 80% power to detect variants 
with Hazard Ratio > 1.4 and MAFs > 0.01.) 
Unlike univariate results, the gene enrichment results from the two analyses were much 
more similar when we look at the gene set enrichments in GO term gene sets. The gene enrichment 
results for FS analysis pointed to cell periphery GO term (GO:0071944, q = 3.23x10-5), synapse 
(GO:0045202, q = 1.63x10-3), neuron part (GO:0097458, q = 1.10x10-3), transmembrane transport 
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(GO:0055085, q = 3.77x10-3), regulation of biological quality (GO:0065008, q = 1.04x10-3), single 
organism signaling (GO:0044700, q = 9.47x10-4), Choline metabolism in cancer (KEGG:05231, 
q = 2.36x10-2) and Neuronal system (REAC:112316, q = 4.76x10-3).   
CC analysis showed significant enrichment of Plasma membrane bounded cell projection 
organization (GO:0120036, q = 4.59x10-5), Dendrite development (GO:0016358, q = 7.08x10-5), 
Homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156, q = 5.67x10-
5), Neuron part (GO:0097458,  q = 2.02x10-5), Synapse (GO:0045202, q = 1.33x10-5), Calcium ion 
binding (GO:0005509, q = 5.38x10-3), Glutamergic synapse (KEGG:04724, q = 2.82x10-4), 
Circadian entrainment (KEGG:04713, q = 2.33x10-4), nitric oxide stimulates guanylate cyclase 
(REAC:392154, q = 5x10-2) and Neuronal system (REAC:112316, q = 3.21x10-2) the gene sets in 
query gene list. For pathway enrichment (KEGG and Reactome) Glutamergic synapse 
(KEGG:04724, q = 2.82x10-4) and Circadian entrainment (KEGG:04713, q = 2.33x10-4) showed 
significant signals. Given that CC analysis did not assume that controls would develop the diseases 
eventually, we believe that this analysis provided somewhat more reliable results for validation 
(and, possibly, treatment).  
CC pathway enrichment analysis gave us two significantly enriched terms that are 
biologically relevant to the MDD pathology. These two terms were Glutamergic synapse 
(KEGG:04724, q = 2.82x10-4) and dendrite development (GO:0016358, q = 7.08x10-5). A copy 
number variation (CNV) study (Glessner et al., 2010), supports Glutamergic synapse. In this 
research, the duplication of chromosomal region (5q35.1) spanning the SLIT3 gene, which codes 
for a protein responsible for cell migration and axon guidance, was observed in 5 unrelated 
individuals with MDD. A pathway analysis on genome-wide association datasets reported that 
Neuroticism association results indicates a significant enrichment in axon guidance Reactome gene 
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set (Kim et al., 2015). A genome wide gene expression study indicated that the postmortem brain 
samples from individuals who committed suicide with or without MDD shows a significant change 
in gene expression of genes involved in GABAergic (inhibitory) and glutamatergic (excitatory) 
neurotransmission (Sequeira et al., 2009).  
Functionally similar genes could be on chromosomal regions close to each other. These 
genes with high LD may inflate the findings in gene set enrichment analysis. We have not 
accounted for the LD structure of SNVs in the gene set enrichment analysis. Another drawback of 
the gene set enrichment analysis is that we could not map all the SNVs to genes. Unmapped 
intergenic SNVs were eliminated in the SNP mapping to gene step (g:SNPense). Also, the SNPs 
which coincide within the overlapping or neighboring genes at extremely close proximity to each 
other may or may not be mapped to all genes in that chromosomal region.  
In gene enrichment results, the same group of genes intersected multiple different GO 
terms neighboring function or structures. This could be observed in FS analysis in which 
Biological Process term had significant enrichment in Cell communication (GO:0007154) and 
Signaling (GO:0023052) GO terms. These two GO terms obviously have overlapping genes in 
their gene sets. Because of this, they both came out as significantly enriched GO terms. This same 
idea also applies to the result of gene set enrichment for CC analysis. The Cellular component 
terms Synapse (GO:0045202, q = 1.33x10-5) and Neuron part (GO:0097458, q = 2.02x10-5) were 
the most significantly enriched gene sets in the query gene list for CC analysis. It is highly probable 
that these two terms have overlapping gene sets, and so both of them are highly enriched. 
The strength of the current study relies on a well-characterized and recruited case group. 
The Han Chinese population is relatively more homogenous than most of the other ethnic groups 
in terms of genetic makeup. We claim that the more homogenous the study population means the 
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more reliable the genetic epidemiology study. However, a significant association finding in one 
ethnic group may not replicate in another ethnic group. So, the findings might not generalize to 
non-Han Chinese population. 
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6. Conclusion 
Sequencing, rather than array based genotyping methods, allows us to study practically all 
non-coding and coding variants in the genome. Two statistical analyses yielded different, albeit 
non-significant, univariate results were due to differences in cohorts analyzed. The pathway 
enrichment results indicated that the suggestive univariate signals showed significant enrichment 
in nervous system cell biology and function. However, suggestive variants sometimes were 
mapped to multiple genes and adjustment for LD structure was not performed. Thus, an additional 
replication cohort may be needed to validate the significant enrichment findings. Nonetheless, 
aggregate results mostly mirror MDD research literature explaining MDD biology as a disorder of 
synaptic transmission systems, ion channels, receptors and dendrite development. However, some 
of the non-neural pathways (e.g. nitric oxide) from the case cohort analysis might provide good 
targets for new treatments. 
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Appendices 
I. R script for the Cox Proportional hazard model run on the VCU VIPBG Light 
cluster 
library(survival) 
library(gtools) 
library(dplyr) 
 
 
data2 <-read.table("/home/projects/CONVERGE/Genos/raw/converge.n11443.dec2014.sample.wrk.txt",sep = "",header = 
TRUE) # phenotype file from initial analysis 
 
csa <- read.table("/home/hgedik/converge_csa_17Feb2017_n10502.txt",sep = "", header = TRUE) # phenotype file with 
CSA and PCs columns after all QC steps completed 
 
data3 <- data2[, c("ID_1", "AAO", "AAO.raw", "AAO.noCSA")] # Subsetting first phenotype file for age at onset 
 
data3[, 5] <- rep("NA", 11443) # Adding a column for getting as much AAO from the phenotype file filling the gaps. 
 
data3$V5 <- as.numeric(data3$V5) 
 
# Filling gaps in AAO column from different columns 
 
for (i in 1:11443) 
{ 
  if (length(as.data.frame(unique(t(data3[i, -1])))[, 1]) == 2) { 
    data3[i, 5] <- as.numeric(na.omit(unique(t(data3[i, -1]))))[1] 
  } 
  else { 
    data3[i, 5] <- as.numeric(unique(t(data3[i, -1])))[1] 
  } 
} 
 
data3 <- data3[, -c(2:4)] 
 
colnames(data3)[c(1:2)] <- c("IID", "AAO") 
 
colnames(csa)[1] <- c("IID") 
 
data3 <- data3[data3$IID %in% csa$IID,] # Subsetting before QC phenotype data frame into a data frame without 
individuals excluded after QC steps 
 
data3 <- merge(data3, csa, by = c("IID"), all.x = T) # Merging data frames by individual ID 
 
data3 <- data3[, c(1, 2, 4:7)] # Excluding extra columns without need 
 
colnames(data3)[c(1:6)] <- c("IID", "AAO", "MDD", "PC1", "PC2", "CSA") # Making sure that column names are exactly the 
same in the following steps 
 
datacase <- data3[data3$MDD == 1,] # Cases are subsetted in one data frame 
 
datacase<-subset(datacase, AAO>=18) 
 
age <- read.table("/home/hgedik/converge_n10502.mdd_plus_covars_v2.txt", sep = "", header = TRUE) # Another 
phenotype file with age at interview column of the control group 
 
age <- age[, c(1, 3, 17)] # Subsetting the data frame for only the age, status and individual ID columns 
 
colnames(age)[1:3] <- c("IID", "MDD", "AAO") # Make sure columns’ names match 
 
datacon <- data3[data3$MDD == 0,] # Controls are subsetted 
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agecon <- age[age$MDD == 0,] # Controls from the phenotype file with age at onset column 
 
mergeCon <- merge(datacon, agecon, by = c("IID"), all.x = T) # Merging two phenotype data frames 
 
mergeCon <- mergeCon[!(is.na(mergeCon$MDD.y) | mergeCon$MDD.y == ""),] # Excluding rows with unidentified case-
control status 
 
mergeCon <- mergeCon[, c(1, 3:6, 8)] 
 
colnames(mergeCon)[1:6] <- c("IID", "MDD", "PC1", "PC2", "CSA", "AAO") 
 
datacon <- mergeCon # Final version of the control dataframe 
 
phenodat <- rbind(datacase, datacon) # Combining rows from control and case data frames 
 
setwd("/home/projects/CONVERGE/Genos/postExcl/recodeA/") # Setting the working directory where genotype files are 
located 
 
file_list <- list.files() # Listing genotype files for looping over to run the Cox regression analysis 
 
file_list <- file_list[-c(1)] # Individual’s genotype file (with .raw extension) name as character array 
 
exfile_list <- grep("chr10+", file_list, perl = TRUE, value = TRUE) 
 
file_list2 <- file_list[!file_list %in% exfile_list] 
 
file_list <- c(exfile_list, file_list2) 
 
file_list2<-gsub(".raw", ".bim", file_list) # Genotype file of SNPs with .bim extension as list of characters 
 
 
if (iseed<=27) 
{ 
  setwd("/home/projects/CONVERGE/Genos/postExcl/recodeA/") 
   
  x6570 <- read.table(paste(file_list[iseed]), sep = "", header = T) # Reading the genotype file into R 
   
  x6570 <- x6570[, -c(1, 3:6)] # Excluding FID and other columns without need for the regression analysis 
   
  x6570wo <- x6570[x6570$IID %in% datacase$IID,] 
   
  x6570wo <- merge(datacase, x6570, by = "IID") # Merging phenotype and genotype data 
   
  x6570 <- x6570[x6570$IID %in% phenodat$IID,] 
   
  x6570 <- merge(phenodat, x6570, by = "IID") # Merging phenotype and genotype data 
   
  x6570$AAO <- as.numeric(x6570$AAO) # Make sure that AAO column is numeric 
  x6570wo$AAO <- as.numeric(x6570wo$AAO) 
   
  setwd("/home/projects/CONVERGE/Genos/postExcl/") 
   
  dat <- read.table(paste(file_list2[iseed]), sep = "", header = F) 
   
  dtf <- dat[rep(seq_len(nrow(dat)), each = 2), ] 
  dtf <- dtf[, -c(3)] 
   
  colnames(dtf)[c(1:5)] <- c("CHR", "SNP", "POS", "AL1", "AL2") 
   
  # Column number which designate the SNP number of each genotype file and also the number of regression run in the 
following for loop. 
   
  nrep<-length(names(x6570)) 
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  #Two empty dataframes for storing the results of regression summary statistics of AS analysis and CC analysis 
respectively 
 
  d301c <- data.frame(coef = rep(0, (nrep - 6)),expcoef = rep(0, (nrep - 6)),secoef = rep(0, (nrep - 6)),Zscore = rep(0, (nrep - 
6)), pvalue = rep(0, (nrep - 6))) 
  d301d <- data.frame(coef = rep(0, (nrep - 6)),expcoef = rep(0, (nrep - 6)),secoef = rep(0, (nrep - 6)),Zscore = rep(0, (nrep - 
6)), pvalue = rep(0, (nrep - 6))) 
   
  for (i in 7:nrep) { 
     
    G5  <- coxph(Surv(x6570$AAO, x6570$MDD) ~  x6570[, i] + PC1 + PC2 + CSA, data = x6570) 
    d301c[i-6, ] <- c(summary(G5)$coefficients[1, 1],summary(G5)$coefficients[1, 2],summary(G5)$coefficients[1, 
3],summary(G5)$coefficients[1, 4],summary(G5)$coefficients[1, 5]) 
     
    G5  <- coxph(Surv(x6570wo$AAO, x6570wo$MDD) ~  x6570wo[, i] + PC1 + PC2 + CSA, data = x6570wo) 
    d301d[i-6, ] <- c(summary(G5)$coefficients[1, 1],summary(G5)$coefficients[1, 2],summary(G5)$coefficients[1, 
3],summary(G5)$coefficients[1, 4],summary(G5)$coefficients[1, 5]) 
  } 
   
  d301c <- cbind(dtf, d301c) 
  d301d <- cbind(dtf, d301d) 
     
  setwd("/home/hgedik/CSA/") 
  write.table(d301c,paste("CSA", seq(1:598)[iseed], ".txt", sep = ""),row.names = F,quote = F) 
   
  setwd("/home/hgedik/CSA/woCSA/") 
  write.table(d301d,paste("CSA", seq(1:598)[iseed], ".txt", sep = ""),row.names = F,quote = F) 
   
} else 
{ 
   
  setwd("/home/projects/CONVERGE/Genos/postExcl/recodeA/") 
   
  x6570 <- read.table(paste(file_list[iseed]), sep = "", header = T) # Reading the genotype file into R 
   
  x6570 <- x6570[, -c(1, 3:6)] # Excluding FID and other columns without need for the regression analysis 
   
  x6570wo <- x6570[x6570$IID %in% datacase$IID,] 
   
  x6570wo <- merge(datacase, x6570, by = "IID") # Merging phenotype and genotype data 
   
  x6570 <- x6570[x6570$IID %in% phenodat$IID,] 
   
  x6570 <- merge(phenodat, x6570, by = "IID") # Merging phenotype and genotype data 
   
  x6570$AAO <- as.numeric(x6570$AAO) # Make sure that AAO column is numeric 
  x6570wo$AAO <- as.numeric(x6570wo$AAO) 
   
  setwd("/home/projects/CONVERGE/Genos/postExcl/") 
   
  dat <- read.table(paste(file_list2[iseed]), sep = "", header = F) 
   
  dat <- dat[, -c(3)] 
  colnames(dat)[c(1:5)] <- c("CHR", "SNP", "POS", "AL1", "AL2") 
   
  # nrep is the column number which designate the SNP number of each genotype file and also the number of regression run 
in the following for loop. 
   
  nrep<-length(names(x6570)) 
    
   
  d301c <- data.frame(coef = rep(0, (nrep - 6)),expcoef = rep(0, (nrep - 6)),secoef = rep(0, (nrep - 6)),Zscore = rep(0, (nrep - 
6)),pvalue = rep(0, (nrep - 6))) 
  d301d <- data.frame(coef = rep(0, (nrep - 6)),expcoef = rep(0, (nrep - 6)),secoef = rep(0, (nrep - 6)),Zscore = rep(0, (nrep - 
6)), pvalue = rep(0, (nrep - 6))) 
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  for (i in 7:nrep) { 
    G5  <-coxph(Surv(x6570$AAO, x6570$MDD) ~  x6570[, i] + PC1 + PC2 + CSA, data = x6570) 
    d301c[i - 6, ] <- c(summary(G5)$coefficients[1, 1],summary(G5)$coefficients[1, 2],summary(G5)$coefficients[1, 
3],summary(G5)$coefficients[1, 4],summary(G5)$coefficients[1, 5]) 
     
    G5  <- coxph(Surv(x6570wo$AAO, x6570wo$MDD) ~  x6570wo[, i] + PC1 + PC2 + CSA, data = x6570wo) 
    d301d[i-6, ] <- c(summary(G5)$coefficients[1, 1],summary(G5)$coefficients[1, 2],summary(G5)$coefficients[1, 
3],summary(G5)$coefficients[1, 4],summary(G5)$coefficients[1, 5]) 
  } 
   
  d301c <- cbind(dat, d301c) 
  d301d <- cbind(dat, d301d) 
   
  setwd("/home/hgedik/CSA/") 
  write.table(d301c,paste("CSA", seq(1:598)[iseed], ".txt", sep = ""),row.names = F,quote = F) 
   
  setwd("/home/hgedik/CSA/woCSA/") 
  write.table(d301d,paste("CSA", seq(1:598)[iseed], ".txt", sep = ""),row.names = F,quote = F) 
   
} 
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II. Query gene list (alphabetical order) of FS analysis for g:GOSt gene set enrichment 
analysis 
Table.7 Query gene list for FS analysis  
AACSP1 AASDH ABCA1 ABCB5 ABHD15-AS1 AC003084.2 AC005276.1 
AC005394
.1 
AC005592.
2 
AC005616.1 AC006041.1 AC006372.4 AC006548.26 AC006548.28 
AC006946
.12 
AC006946.
16 
AC006946.17 AC007131.1 AC007551.2 AC007682.1 AC009120.4 
AC009501
.4 
AC009961.
3 
AC010127.3 AC010731.3 AC010731.4 AC017060.1 AC018359.1 
AC018359
.3 
AC018731.
3 
AC018755.18 AC053503.2 AC064853.2 AC064875.2 AC068196.1 
AC073283
.4 
AC087430.
1 
AC090505.6 AC091878.1 AC092071.1 AC092384.1 AC092684.1 
AC096558
.1 
AC098784.
1 
AC104820.2 AC135999.2 ACO2 ACOT9 ACOXL 
ACSS3 ADAM23 ADAMTS9-
AS2 
ADGRE5 ADGRV1 ADK AF064858.6 
AGBL1 AGBL1-
AS1 
AKAP13 AL021546.6 AL022397.1 AL163953.3 ALLC 
ALPK1 AMFR ANGPT1 ANK2 ANKRD9 ANKRD22 ANKS1A 
ANP32B AP000695.
6 
AP000696.2 AP001043.1 APRT AQP6 AQP7 
AQP10 ARF4P3 ARHGEF3 ARHGEF10 ARMC7 ARMCX4 ASB3 
ASB5 ASCC2 ASCC3 ASH2L ASIP ASS1 ASTE1 
ATF1P1 ATP2C1 ATP8A2 ATP8B2 ATP10B ATXN7L1 AXDND1 
BASP1 BBX BICD1 BLOC1S1 BMP2K BMP6 BMP8B 
BMPR1B BMS1P20 BNIP3L BPIFB1 BRINP2 C2ORF54 C2ORF83 
C5ORF66 C6 C8ORF86 C9ORF72 C9ORF129 C10orf103 C16ORF90 
C19ORF4
4 
C19ORF84 CACNB1 CACNB4 CADM1 CADPS CADPS2 
CASC4 CCDC3 CCDC146 CCL17 CCL24 CD19 CD47 
CD200R1 CD200R1L CD276 CD302 CDC42BPA CDC42EP3 CDH13 
CDHR3 CDK13 CDK14 CEBPG CECR7 CEP83 CETN3 
CFAP70 CFAP77 CHCHD3 CHM CHPT1 CKLF-
CMTM1 
CLEC4C 
CMIP CNBD1 CNGB1 CNR2 CNTLN CNTNAP2 COL4A2 
COL13A1 COL23A1 COLEC12 COLQ COQ3 COQ8A CPA6 
CPNE2 CPSF7 CPVL CRADD CSMD1 CSMD2 CSRNP3 
CTA-
747E2.10 
CTAGE1 CTB-1I21.2 CTB-13L3.1 CTB-91J4.1 CTC-232P5.1 CTC-
338M12.9 
CTC-
436P18.1 
CTC-
471J1.2 
CTC-512J12.4 CTC-
513N18.7 
CTC-
548K16.5 
CTCFL CTD-
2009A10.1 
CTD-
2021H9.1 
CTD-
2086L14.1 
CTD-
2143L24.1 
CTD-
2357A8.2 
CTD-2373J6.1 CTD-
2374C24.1 
CTD-
2516F10.2 
CTD-
2528L19.3 
CTD-
2528L19.4 
CTD-
2528L19.6 
CTD-
2535I10.1 
CTD-
2554C21.1 
CTD-
2560C21.1 
CTD-
2619J13.3 
CTD-
3064H18.4 
CTD-
3222D19.2 
CTNNA3 CYFIP1 CYP2AB1P CYP2B7P CYSTM1 
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CYTH1 DACH1 DACH2 DAPK2 DCAF8L2 DCC DCLK1 
DDX11-
AS1 
DDX53 DEFB110 DGKB DGKG DGKI DIAPH3 
DISC1FP1 DISP3 DKK3 DLGAP1 DNAJC5 DNAJC12 DNAJC19P1 
DNM3 DNMT1 DOCK3 DOK6 DOPEY2 DPH6-AS1 DSCAML1 
DUTP3 DYM DYTN EBF1 EDARADD EEF1A1P22 EEF1B2P3 
EFCAB6 EFHD2 EGFEM1P EHBP1 EHMT1 EIF4EBP2P3 ELMO1 
EMCN ENPP6 ENSG000001
43248 
ENSG000001
82957 
ENSG000002
06885 
ENSG000002
39265 
ENSG000002
71798 
EPCAM EPM2A EPSTI1 ERC2 ERO1A ERVMER61-
1 
ESR1 
ESR2 ETS2 ETV5 ETV5-AS1 ETV6 EXOC2 F2RL2 
F13A1 FAAP24 FAM43B FAM66C FAM69C FAM78B FAM90A1 
FAM135A FAM160A
2 
FAM160B2 FAM174B FAM181A-
AS1 
FAM189A1 FAM214A 
FAR2 FBLN2 FBXL17 FBXW7 FGF19 FGFR1OP2P1 FHIT 
FHL5 FMN2 FMO7P FOXG1-AS1 FOXP2 FRMD1 FRMD4A 
FRMD5 FSTL4 FYN GABRB1 GABRB3 GALNS GALNT13 
GAPDHP2
2 
GAPDHP5
5 
GAS2 GFRA2 GGA3 GLB1L2 GLB1L3 
GLI2 GNAO1 GNPTAB GNRHR GOLPH3L GPC5 GPC5-AS2 
GPHN GPR18 GPR183 GRAMD1B GRID2 GRIK2 GRIK4 
GRM7 GSTM1 GSTM2 GSTM5 GTF2F2P2 GTPBP2 GTPBP3 
H2AFY H2AFZP3 HCG2040054 HCN1 HCRTR2 HDAC4 HDAC9 
HERC4 HERPUD2 HHAT HMGB1P1 HMGB3P4 HMGN2P22 HMGN2P35 
HNRNPA
1P54 
HORMAD
1 
HS3ST4 HSPB8 HSPE1P19 IGFBP7 IGSF9B 
IGSF11 IL1RL1 IL10RA IL17RA IL18R1 INPP1 IPCEF1 
IQCA1L IQGAP2 ITGA7 ITM2A KAZN KCNA5 KCND2 
KCNH1 KCNJ6 KCNK12 KCNMB2 KCNMB2-
AS1 
KCTD8 KIAA0040 
KIAA0232 KIAA0930 KIAA1211 KIAA1462 KIFAP3 KIRREL KLHL23 
KREMEN
1 
KRTAP21-
4P 
L3MBTL4 LA16C-
306E5.3 
LANCL1-AS1 LCOR LHPP 
LIFR LILRP1 LIM2 LINC00238 LINC00276 LINC00378 LINC00434 
LINC0050
4 
LINC0051
1 
LINC00520 LINC00536 LINC00882 LINC00923 LINC01102 
LINC0112
2 
LINC0117
0 
LINC01310 LINC01314 LINC01377 LINC01435 LINC01482 
LINGO2 LL22NC03
-80A10.6 
LLGL2 LMCD1 LMCD1-AS1 LMNTD1 LPAL2 
LPGAT1 LPIN1 LPIN2 LPP LRP1 LRP1-AS LRP1B 
LRRC1 LRRIQ4 LRRTM4 LRSAM1 LUZP2 LY75-CD302 LYAR 
MAD2L1
BP 
MAGEC3 MALRD1 MAPK6 MAPKAP1 MARCH7 MBP 
MCF2 MCHR2 MECOM METAZOA_S
RP 
MGAT5B MIR585 MIR605 
MIR607 MIR623 MIR3681HG MIR4448 MIR4453 MIR4697HG MIR4754 
MIR5689
HG 
MIRLET7
DHG 
MLEC MOB3B MPP4 MPPE1 MRC2 
MROH2B MRPL22P
1 
MRPL48P1 MRPL49P1 MRPS21P8 MSH2 MSRA 
MTCYBP
45 
MTMR3 MYO18B MYRIP NA NALCN NALCN-AS1 
53 
 
NANS NAV2 NEK11 NELL1 NFATC2IP NFIA NFIA-AS1 
NIPSNAP
1 
NLGN1 NOSTRIN NOVA1-AS1 NPAS3 NRG2 NRG3 
NTM NTRK3 NUDT18 NUF2 NUP85 NXPH1 OCA2 
OLFML2
A 
OPRM1 OR2AH1P OR2D2 OR5AR1 OR10Y1P OR51R1P 
OSBP2 OXCT2 PAH PALM2 PARK2 PARL PARVA 
PAX5 PAXIP1 PAXIP1-AS2 PBX3 PCAT29 PCDH15 PCLO 
PCNP PCSK5 PCYT1B PCYT1B-AS1 PDE4B PDE4D PDE10A 
PDIA5 PDZD7 PEPD PEX14 PFDN1 PGM1 PHBP4 
PHOSPH
O2 
PIK3C2G PIK3C3 PITPNC1 PLA2G4E PLA2G4E-
AS1 
PLA2G4F 
PLA2R1 PLEKHA7 PLGRKT PNP POLA1 POLR2A POTEI 
PPARGC1
A 
PPFIA2 PPFIBP1 PRAMEF25 PRB4 PRDM16 PRDX4 
PRELID2 PRICKLE2 PRKACB PRKG1 PRLR PROS2P PRPH 
PRTFDC1 PSD3 PSMA2P1 PSME4 PTCHD1-AS PTPRC PTPRD 
PTPRN2 PVT1 QKI RABEP2 RACGAP1 RAD1P1 RAD51B 
RALYL RANP2 RAP1GAP2 RAPGEF5 RBFOX1 RERGL RGS6 
RGS7 RHPN2 RIT2 RN7SL66P RN7SL301P RN7SL344P RN7SL394P 
RN7SL56
1P 
RN7SL756
P 
RNF152 RNF220 RNF225 RNU4-71P RNU6-230P 
RNU6-
235P 
RNU6-
310P 
RNU6-331P RNU6-481P RNU6-523P RNU6-638P RNU6-651P 
RNU6-
666P 
RNU6-
712P 
RNU6-743P RNU6-815P RNU6-918P RNU6-988P RNU6-1104P 
RNU6-
1250P 
RNU7-48P ROBO2 ROR1 ROR2 RORA RP1-41C23.1 
RP1-
97J1.2 
RP1-
118J21.24 
RP1-
118J21.25 
RP1-164F3.8 RP3-434P1.6 RP3-
468K18.7 
RP4-536B24.3 
RP4-
536B24.4 
RP4-
597J3.1 
RP4-
725G10.3 
RP4-736H5.3 RP4-
785G19.5 
RP5-
837O21.2 
RP5-
887A10.1 
RP5-
933B4.1 
RP5-
937E21.1 
RP5-972B16.2 RP5-1069C8.2 RP5-1101C3.1 RP11-1L9.1 RP11-6N13.1 
RP11-
9L18.2 
RP11-
9L18.3 
RP11-14I17.3 RP11-17P16.1 RP11-17P16.2 RP11-22B23.1 RP11-22B23.2 
RP11-
22H5.2 
RP11-
24J19.1 
RP11-24P4.1 RP11-30G8.2 RP11-30J20.1 RP11-
32D16.1 
RP11-
42H13.1 
RP11-
42O15.2 
RP11-
50B3.2 
RP11-57C13.3 RP11-57C13.6 RP11-
57G10.8 
RP11-61O1.1 RP11-61O1.2 
RP11-
64B16.5 
RP11-
72M17.1 
RP11-75I2.3 RP11-80H8.4 RP11-80I3.1 RP11-93G5.1 RP11-
111D3.2 
RP11-
114H23.1 
RP11-
115A15.4 
RP11-
120M18.2 
RP11-
121G22.3 
RP11-
122G18.7 
RP11-
131H24.5 
RP11-
132A1.6 
RP11-
137P24.5 
RP11-
141M1.3 
RP11-
152L20.3 
RP11-
161H23.9 
RP11-165E7.1 RP11-
166N6.2 
RP11-
168O22.1 
RP11-
174O3.3 
RP11-
180K7.1 
RP11-217B7.2 RP11-
217L21.1 
RP11-
234A1.1 
RP11-
237D3.1 
RP11-239C9.1 
RP11-
243A14.1 
RP11-
244F12.1 
RP11-
264B17.2 
RP11-
264B17.3 
RP11-
264B17.4 
RP11-
264B17.5 
RP11-
265N7.2 
RP11-
266K4.1 
RP11-
276E17.2 
RP11-
278H7.1 
RP11-290L1.7 RP11-
306G20.1 
RP11-
307N16.6 
RP11-
314P15.2 
RP11-
342M3.5 
RP11-
347H15.1 
RP11-
354I13.2 
RP11-
359E10.1 
RP11-364B6.2 RP11-
369E15.2 
RP11-
369E15.4 
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RP11-
385J1.3 
RP11-
386M24.9 
RP11-
396O20.2 
RP11-
397C12.1 
RP11-
403P17.2 
RP11-
406O16.1 
RP11-
410D17.2 
RP11-
413H22.2 
RP11-
420K14.8 
RP11-
420N3.2 
RP11-
420N3.3 
RP11-
421P23.1 
RP11-
429A20.2 
RP11-
429A20.3 
RP11-
429A20.4 
RP11-
436D23.1 
RP11-
436F21.1 
RP11-
443C10.1 
RP11-
443C10.2 
RP11-
443C10.3 
RP11-
444A22.1 
RP11-
446J8.1 
RP11-
451O13.1 
RP11-
453E17.3 
RP11-
453E17.4 
RP11-
462G2.2 
RP11-
466A19.6 
RP11-
466A19.8 
RP11-
467H10.2 
RP11-
474D1.3 
RP11-
474D1.4 
RP11-479J7.1 RP11-486E2.1 RP11-
486G15.1 
RP11-
486G15.2 
RP11-
503E24.2 
RP11-
513G11.3 
RP11-
525K10.2 
RP11-
525K10.3 
RP11-
535A5.1 
RP11-
535C21.3 
RP11-
539E19.2 
RP11-
543A18.1 
RP11-
543H23.2 
RP11-
550A9.1 
RP11-
552D8.1 
RP11-
565A3.2 
RP11-
570L15.2 
RP11-
589M4.2 
RP11-
589M4.3 
RP11-
613M10.9 
RP11-
622A1.1 
RP11-624L4.1 RP11-646I6.5 RP11-
650J17.1 
RP11-
665G4.1 
RP11-
671P2.1 
RP11-
696F12.1 
RP11-
713P17.3 
RP11-
713P17.5 
RP11-
728G15.1 
RP11-
737O24.3 
RP11-
748L13.7 
RP11-
753E22.2 
RP11-
753E22.3 
RP11-
757O6.4 
RP11-777F6.3 RP11-
793A3.2 
RP11-
797H7.6 
RP11-
813I20.2 
RP11-
815J21.1 
RP11-
817I4.1 
RP11-817I4.2 RP11-
849N15.4 
RP11-
849N15.5 
RP11-
855A2.1 
RP11-
855A2.3 
RP11-
862P13.1 
RP11-
863N1.4 
RP11-871F6.3 RP11-936I5.1 RP11-
1398P2.1 
RP13-
497K6.1 
RPH3A 
RPL7AP3
1 
RPL7L1P1
0 
RPL7P13 RPL12P8 RPL17P35 RPL23AP29 RPL30P13 
RPL31P52 RPS3AP38 RPS4XP20 RPS4XP23 RPS5 RPS6KA2 RPS6P23 
RPS8P4 RPSAP31 RPTOR RREB1 RSU1 RUNX1 RYR2 
RYR3 S1PR2 SATB1-AS1 SCARB1 SCARNA23 SCFD2 SCHIP1 
SCN3B SCN7A SCN9A SDHAF2 SDHC SDK2 SEC14L5 
SEC22A SEL1L SEMA5A SEPT7 SEPT7-AS1 SEPT9 SERTAD4 
SFXN3 SGCD SGCG SGCZ SGK223 SGO1-AS1 SHANK2 
SHB SIGLEC5 SIPA1L2 SIPA1L3 SIRPB3P SIRT1 SIX4 
SLC2A13 SLC8A1-
AS1 
SLC10A2 SLC12A8 SLC13A3 SLC14A2 SLC14A2-
AS1 
SLC15A1 SLC20A2 SLC22A2 SLC22A3 SLC22A10 SLC22A14 SLC22A23 
SLC24A2 SLC25A18 SLC25A37 SLC27A6 SLC29A4 SLC35D2 SLC35F1 
SLC44A1 SLC52A3 SLIT1 SLIT3 SMAD4 SMAP1 SMCO4 
SMIM19 SMKR1 SNHG18 SNRPD3 SNTG1 SOCS4 SORCS1 
SORCS2 SOX9-AS1 SPC25 SPNS1 SPPL3 SPTBN1 SRGAP1 
ST3GAL1
P1 
ST6GALN
AC3 
ST13P19 STAC STAM2 STAP1 STARD13 
STAT6 STEAP1B STOML3 STUM STYX SVEP1 SWAP70 
SYNE2 SYNJ2 SYT9 SYT14 TAS2R1 TBC1D5 TBXAS1 
TDRD9 TEAD1 TECPR2 TEKT3 TENM2 TENM4 TIAL1 
TIGAR TM4SF19-
AS1 
TM4SF19-
TCTEX1D2 
TMCO4 TMEM55B TMEM94 TMEM132B 
TMEM132
D 
TMEM135 TMEM185A TMEM261 TNR TP53I13 TPM3P3 
TRIB3 TRIM14 TRIM21 TRMT10C TRPC5 TRPS1 TSPAN7 
TSPAN8 TTC7B TTC21B TTC39B TWSG1 TXNL1 UBA6 
UBA6-
AS1 
UBAC2 UBAC2-AS1 UBE2CP3 UBXN7 UBXN7-AS1 UCKL1 
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UHRF1BP
1 
ULK4 UNC5C VCAN VN1R9P VN1R31P VN1R32P 
VPS54 VWDE WDHD1 WDR7 WDR25 WDR70 WIPI1 
WNK2 Y_RNA YES1 YRDCP3 ZBED3-AS1 ZC2HC1B ZCCHC24 
ZFP30 ZMAT4 ZMYND12 ZNF100 ZNF124 ZNF229 ZNF423 
ZNF500 ZNF525 ZNF540 ZNF571 ZNF571-AS1 ZNF573 ZNF584 
ZNF607 ZNF626 ZNF670 ZNF670-
ZNF695 
ZNF733P ZNF781 ZNF793 
ZNF804A ZNF837 ZNF841 ZSCAN5A    
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III. Query gene list (alphabetical order) of CC analysis for g:GOSt gene set enrichment 
analysis 
Table.8 Query gene list for CC analysis  
ABCC3 ABCD2 ABCG4 ABHD2 AC003092.1 AC004901.1 AC004941.3 
AC005034.2 AC005062.2 AC005387.2 AC005775.
2 
AC006042.7 AC006372.5 AC006466.5 
AC006548.28 AC007128.1 AC007349.7 AC007682.
1 
AC009403.2 AC010136.2 AC011288.2 
AC012074.2 AC012354.6 AC012368.1 AC012501.
2 
AC013463.2 AC018816.3 AC018890.6 
AC020743.2 AC024560.3 AC037459.4 AC069277.
2 
AC079610.2 AC092684.1 AC092687.3 
AC092798.2 AC096579.1
5 
AC096649.3 AC100802.
3 
AC104306.4 AC104667.3 AC118754.4 
AC132008.1 ACA64 ACEA_U3 ACSL3 ACTBP2 ADAMTS16 ADAMTSL
1 
ADCY9 ADGB ADGRD1 ADGRE5 ADGRL2 AEBP2 AGAP3 
AGBL1 AGFG1 AHCYL2 ALDH1A2 ALK ALPK2 AMPH 
ANGPT2 ANKRD7 ANKS1A ANXA2P3 AP000282.2 AP000462.3 AP000619.6 
AP001347.6 AP002856.4 AP1G1 AQP4-AS1 ARF4P3 ARFIP2 ARL8A 
ARL15 ARSB ASB11 ASPN ASTN2 ATG13 ATP2B2 
ATP5B ATP6V0A4 ATP6V1C2 ATP8A2P3 ATP8B4 ATP10B B3GLCT 
B3GNTL1 BACE1 BACE1-AS BAZ2A BBC3 BCL11B BEND3P2 
BIN3 BMP6 BMX BNIP3P13 BPI BRCC3 BTBD11 
BTC C1ORF50 C2CD2L C2ORF88 C3 C4ORF22 C6ORF229 
C7ORF72 C8ORF37-
AS1 
C8ORF58 C9ORF57 C10ORF90 C10ORF113 C11ORF40 
C12ORF40 C16ORF90 C19ORF60 CACNA1C CACNA1C-
IT2 
CACNA1G CACNA1H 
CADM1 CARD14 CARMIL1 CBL CCAR2 CCBE1 CCDC7 
CCDC18 CCDC18-
AS1 
CCDC30 CCDC40 CCDC61 CCDC88C CCDC105 
CCDC146 CCDC153 CCDC171 CCDC190 CCNL1 CCNYL1 CCSER1 
CD1D CD44 CD300LF CDC5L CDC20 CDC42SE2 CDCA3 
CDH13 CDH18 CDH20 CDHR3 CDK5 CDYL2 CELF2 
CENPP CEP78 CEP128 CEP164P1 CEP250 CERK CERS4 
CETP CFAP47 CH17-262A2.1 CHCHD3 CHD6 CHD7 CHN2 
CLEC4C CLNK CLRN3 CMB9-
94B1.2 
CMC4 CMIP CNTLN 
CNTN4 CNTN5 COBL COL4A4 CORO2B CPA6 CPLX2 
CPXM2 CRLF1 CSGALNACT1 CSMD1 CSMD3 CSRNP3 CTA-
221G9.12 
CTA-392E5.1 CTB-
22K21.2 
CTB-52I2.4 CTB-
118P15.2 
CTB-
158E9.1 
CTBP2P8 CTC-
360J11.5 
CTC-
360J11.6 
CTC-
394G3.2 
CTC-432M15.3 CTC-
459M5.2 
CTC-
471J1.8 
CTC-512J12.4 CTC-
512J12.6 
CTC-
548K16.5 
CTD-
2007H18.1 
CTD-2010I16.1 CTD-
2043I16.1 
CTD-
2066L21.3 
CTD-
2147F2.1 
CTD-
2297D10.1 
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CTD-
2308N23.2 
CTD-
2354A18.1 
CTD-2525I3.2 CTD-
2534I21.8 
CTD-
2619J13.3 
CTD-
2619J13.13 
CTD-
3006G17.2 
CTD-
3020H12.3 
CTD-
3020H12.4 
CTD-
3128G10.7 
CTNND2 CTSB CXCL13 CYB5AP4 
CYP7B1 DAB1 DACH1 DCC DCUN1D5 DDX11 DDX19A 
DDX39A DENND1A DESI1 DIO2-AS1 DLEU1 DLGAP1 DMD 
DMXL2 DNAH5 DNAJC3 DOCK1 DOCK8 DOK7 DPH6 
DPH6-AS1 DPP6 DPYD DR1 DRC1 DSCAM DTNB 
DUXA DYNC2H1 ECM2 EEF2KMT EEFSEC EFR3A EIF2D 
EIF4A3 ELF2 ELL2P1 ELMOD1 ELOVL1 EMID1 EMP1 
ENOX1 ENPEP ENPP7P14 EPB41L4A ERC1 ERC2 ERG 
ERMAP ESR1 ESRRG EXT1 EZH2 F8 F11-AS1 
FA2H FADS2 FAM19A5 FAM81B FAM129A FAM169B FAM189A1 
FANCC FANCD2P2 FAP FARP1 FARS2 FASTK FAT1 
FBN1 FBXO21 FCRL2 FDPSP3 FGD2 FGD6 FGFBP1 
FGFR1 FGGY FHIT FILIP1 FKBP8 FNIP1 FPR1 
FREM3 FRMD1 FRMPD4 FSTL4 FSTL5 FTH1P24 FTLP12 
FUNDC2 FXYD6 FXYD6-
FXYD2 
GAA GAB4 GALNT9 GAS7 
GBP1P1 GCH1 GFRA1 GJA8 GLDC GLDN GLYR1 
GMNN GNB3 GNG12-AS1 GNGT1 GNL2P1 GNL3L GPATCH8 
GPCPD1 GRAMD1C GRHL2 GRIK2 GRIP1 GRM7 GRM7-AS3 
GSN GUSBP5 HACD2 HDAC4 HDAC9 HECA HHIPL1 
HINFP HIST1H4E HKDC1 HMCN2 HMGA2 HMGB1 HMGN1P11 
HNRNPA1P6
0 
HRCT1 HSBP1L1 HTR1DP1 HTRA1 HYI HYI-AS1 
IARS IFT57 IGFBP7-AS1 IGKC IGSF9B IL1RAPL2 IMMP2L 
INSR INTS10 IPPK IQCJ IQCJ-
SCHIP1 
ITGA8 ITPR1 
ITPR1-AS1 ITPR3 ITSN2 JARID2 KALRN KANK1 KATNBL1P
6 
KB-
1562D12.1 
KCNA1 KCND3 KCNH5 KCNIP4 KCNJ3 KCNK6 
KCNMA1 KCNMA1-
AS1 
KCNMB2 KCNMB2-
AS1 
KCNQ5 KIAA0232 KIAA1143 
KIAA1211L KIAA1217 KIAA1328 KIAA1549 KIAA1671 KIAA1755 KIF18B 
KIF21A KLHL1 KLRC2 KLRC3 KRT8P45 KRT18P34 KSR2 
LA16C-
306E5.1 
LA16C-
306E5.3 
LAMA5 LAMC3 LDB2 LDLRAD3 LDLRAD4 
LGALS9DP LHFPL3 LINC00113 LINC00374 LINC00442 LINC00504 LINC00547 
LINC00578 LINC00582 LINC00643 LINC00644 LINC00824 LINC00870 LINC00877 
LINC01016 LINC01035 LINC01036 LINC01056 LINC01073 LINC01250 LINC01266 
LINC01299 LINC01317 LINC01322 LINC01331 LINC01435 LINC01501 LINC01592 
LINC01627 LINC01629 LINC01706 LINC01722 LINC01749 LINC01807 LINC01828 
LINC01850 LINC01926 LINC01929 LINC01933 LINC01992 LINC02008 LINC02017 
LINC02055 LINC02071 LINC02174 LINC02196 LMCD1-
AS1 
LMNTD1 LNP1 
LPP LRP1B LRRC8B LRRC31 LRRIQ4 LUZP2 LYSMD4 
LYST MAD1L1 MAGI2 MAP1B MAP3K4 MAPKAP1 MARC2 
MARCH1 MBOAT1 MBP MBTPS1 MCAM MCC MCF2L 
MCPH1 MED8 METAZOA_SR
P 
METTL15 MFSD9 MGAT4C MGC16275 
MICU3 MIGA1 MIR181A1HG MIR769 MIR3651 MIR3941 MIR4308 
MIR4475 MIR4479 MIR4525 MIR4662B MIR4670 MIR4697HG MIR4754 
58 
 
MIR5190 MIR6734 MIR6756 MIR7114 MIR8062 MITF MKRN7P 
MLC1 MMP1 MMP20 MOB3B MORF4L1 MPL MRPL45 
MRPS22 MS4A4A MSI2 MSLN MTAP MTCP1 MTCYBP28 
MTF2 MTG2 MTHFD2P7 MUC4 MVB12B MYH14 MYLK 
MYLKP1 MYOM2 MYRIP NALCN-
AS1 
NDUFA3P2 NDUFA5 NDUFS4 
NEBL NEDD4L NGLY1 NINJ2 NIPAL1 NIPAL3 NIPBL 
NIT2 NKAIN2 NLGN4X NLRX1 NME1 NME1-NME2 NMNAT1 
NNT NOL8 NOS1 NOS2 NOX4 NPM1P30 NR2C1 
NREP NRG3 NRXN3 NSMF NSRP1P1 NXPH1 OGN 
OMD OPHN1 OR7A3P OR7E66P OR7E129P OR11K1P OSGEP 
OTOF P3H1 P3H3 PABPC1P1
0 
PALM2 PAPPA2 PCDH9 
PCDH11X PCDHA1 PCDHA4 PCDHA8 PCED1B PCED1B-AS1 PCLO 
PDE1C PDE7B PDE8B PDLIM2 PDZD3 PELI1 PEMT 
PGLYRP1 PHACTR3 PHF2P2 PIF1 PIGA PIP5K1B PIR 
PKD1L2 PKHD1 PKIB PKN2 PKN2-AS1 PLCB1 PLCB1-IT1 
PLCH1 PLEKHA1 PLEKHA8 PLEKHG6 PLS3-AS1 PLXNC1 PM20D1 
PNLIPP1 PNMAL1 POC1B POLA1 POLR2H POLR2M POU5F1P6 
PPP6R3 PQLC1 PQLC2L PRDM11 PRDM16 PREX1 PRKCA 
PRKG1 PRKG1-AS1 PROX1 PRPF39 PRR20A PRR20C PRR27 
PRSS46 PRSS50 PRUNE2 PSAT1 PSD3 PSMB6 PTAR1 
PTCHD1-AS PTGES3P5 PTPRB PTPRD PTPRE PTPRN2 PTPRT 
PTTG1IP PVT1 RAB9A RAB14 RAB17 RAB37 RAB40B 
RAD51B RAD52 RAPGEF6 RASGEF1
B 
RASGEF1C RASGRF2 RASSF5 
RBFOX1 RBFOX3 RBM33 RBM41 RBM47 RBMS3 RELN 
RERE RFPL4AP6 RFWD2 RGS7 RHBDL2 RIMS3 RN7SKP165 
RN7SKP228 RN7SKP269 RN7SL391P RN7SL714
P 
RNA5SP14
6 
RNA5SP309 RNF6 
RNF38 RNF138P2 RNF165 RNF214 RNF217 RNF225 RNLS 
RNU4-56P RNU4-86P RNU5A-2P RNU6-7 RNU6-8 RNU6-75P RNU6-125P 
RNU6-192P RNU6-262P RNU6-300P RNU6-
347P 
RNU6-
1090P 
RNU7-6P ROBO1 
ROBO2 ROGDI RP1-34B20.4 RP1-
35C21.2 
RP1-
68D18.4 
RP1-
90G24.10 
RP1-91J24.3 
RP1-92O14.3 RP1-
92O14.6 
RP1-228P16.3 RP1-
228P16.4 
RP1-
251M9.3 
RP1-
292B18.4 
RP1-
297M16.2 
RP3-
331H24.5 
RP3-
369A17.6 
RP3-399J4.2 RP3-
422G23.3 
RP3-
428L16.2 
RP3-468B3.2 RP4-
569D19.5 
RP4-
612C19.1 
RP4-
612C19.2 
RP4-663N10.2 RP4-
669H2.1 
RP4-
678D15.1 
RP4-713B5.2 RP4-
717I23.2 
RP5-
864K19.4 
RP5-
994D16.9 
RP5-994D16.12 RP5-
1054A22.4 
RP5-
1106E3.1 
RP11-6O2.2 RP11-8L2.1 
RP11-8L8.2 RP11-
10K17.6 
RP11-19J3.5 RP11-
21L1.1 
RP11-
25L3.1 
RP11-25L3.3 RP11-
28A22.2 
RP11-32K4.1 RP11-
33I11.2 
RP11-53B2.1 RP11-
61G19.1 
RP11-
62C3.6 
RP11-62C3.8 RP11-
62C3.10 
RP11-63E5.6 RP11-64I5.1 RP11-70F11.8 RP11-
74K11.2 
RP11-
75C9.2 
RP11-76E12.1 RP11-
78A18.2 
RP11-
81A22.5 
RP11-
83M16.6 
RP11-84A14.4 RP11-
87F15.2 
RP11-
93K22.6 
RP11-97E7.1 RP11-
98E6.1 
RP11-
105N14.2 
RP11-
110J1.2 
RP11-115J16.2 RP11-
118H4.1 
RP11-
135F9.3 
RP11-
143K11.5 
RP11-
145E5.5 
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RP11-
150C16.1 
RP11-
154D6.1 
RP11-154D17.1 RP11-
158D2.2 
RP11-
161D15.1 
RP11-
161D15.2 
RP11-
171I2.1 
RP11-
172F10.1 
RP11-
173A6.3 
RP11-175E9.1 RP11-
175E9.2 
RP11-
192P3.4 
RP11-
196H14.3 
RP11-
196H14.4 
RP11-
202H2.1 
RP11-
203M5.6 
RP11-203M5.7 RP11-
204C23.1 
RP11-
208K4.1 
RP11-212E8.1 RP11-
213G6.2 
RP11-
215A19.2 
RP11-
215D10.1 
RP11-231C18.3 RP11-
235P11.1 
RP11-
239H6.2 
RP11-
242C24.2 
RP11-
242C24.3 
RP11-
242P2.1 
RP11-
243M5.5 
RP11-252C24.3 RP11-
255E6.6 
RP11-
259A24.1 
RP11-
263G22.1 
RP11-
264M12.4 
RP11-
266O8.1 
RP11-
277P12.6 
RP11-280O1.2 RP11-
281H11.1 
RP11-
283G6.5 
RP11-
283G6.6 
RP11-
285G1.15 
RP11-
305B6.1 
RP11-
305B6.3 
RP11-305P14.1 RP11-
315L6.1 
RP11-
317M11.1 
RP11-
326A19.3 
RP11-
331H2.4 
RP11-
334C17.3 
RP11-
334C17.5 
RP11-334C17.6 RP11-
342M1.3 
RP11-
342M21.2 
RP11-
355I22.2 
RP11-
359B12.2 
RP11-
363G15.2 
RP11-
366L20.3 
RP11-375N15.1 RP11-
382E9.1 
RP11-
384F7.1 
RP11-385J1.3 RP11-
391L3.4 
RP11-
391L3.5 
RP11-
391M7.3 
RP11-404O13.4 RP11-
405M12.2 
RP11-
410D17.2 
RP11-
429A20.3 
RP11-
430H10.2 
RP11-
430H10.4 
RP11-
431D12.1 
RP11-433A10.3 RP11-
434D9.2 
RP11-
435F13.2 
RP11-
436D23.1 
RP11-
436F21.1 
RP11-
442J17.3 
RP11-
445O3.2 
RP11-485F13.1 RP11-
492I21.1 
RP11-
497K15.1 
RP11-
505D17.1 
RP11-
507B12.2 
RP11-
510J16.5 
RP11-
513H8.1 
RP11-525K10.3 RP11-
526F3.1 
RP11-
529K1.3 
RP11-
531H8.1 
RP11-
531H8.2 
RP11-
538C21.2 
RP11-
548M13.1 
RP11-550I24.2 RP11-
550I24.3 
RP11-
555M1.3 
RP11-
558A11.2 
RP11-
563P16.1 
RP11-
570K4.1 
RP11-
586K2.1 
RP11-593P24.4 RP11-
597G23.1 
RP11-
638L3.1 
RP11-
654A16.3 
RP11-
655H13.2 
RP11-
657O9.1 
RP11-
669I1.1 
RP11-669N7.2 RP11-
672L10.5 
RP11-
673E1.4 
RP11-
677O4.5 
RP11-
689P11.2 
RP11-
689P11.3 
RP11-
690J15.1 
RP11-691H4.4 RP11-
707P17.1 
RP11-
736K12.1 
RP11-
764D10.2 
RP11-
767N15.1 
RP11-
779P15.2 
RP11-
817J15.2 
RP11-817J15.3 RP11-
849N15.4 
RP11-
901H12.1 
RP11-
1016B18.1 
RP11-
1082L8.3 
RP11-
1094M14.5 
RP11-
1094M14.8 
RP11-
1105O14.1 
RP11-
1365D11.1 
RP13-
143G15.4 
RP13-
580F15.2 
RPIAP1 
RPL7AP8 RPL21P39 RPL26P9 RPL31P13 RPL36AP10 RPL38 RPN1 
RPRM RPS5 RPS26P54 RPUSD4 RSU1 RTN4 RTN4R 
RUNX1 RXFP2 SAE1 SAGE4P SATB1-AS1 SCARNA11 SCFD2 
SCG5 SCHLAP1 SCML2 SCNN1A SDC3 SDK1 SEC14L5 
SEH1L SEMA4D SERINC2 SETD7 SETDB1 SGCD SGCZ 
SGO1-AS1 SHANK2 SHISA9 SIX4 SLAIN2 SLC1A2 SLC1A6 
SLC2A14 SLC4A2 SLC5A4 SLC6A5 SLC6A15 SLC22A2 SLC22A10 
SLC24A2 SLC24A3 SLC27A6 SLC28A3 SLC35G4 SLC38A11 SLC44A3 
SLC44A3-
AS1 
SLFN12L SLIT3 SMAD3 SNORA31 SNORA64 SNORA67 
SNORA84 SNX2P2 SNX29 SORBS2 SORCS1 SORCS2 SPAAR 
SPAG16 SPATA4 SPATC1L SPCS3 SPHKAP SPNS3 SPOCK1 
SPOCK3 SRGAP1 SSPN SSTR1 SSU72P8 ST6GALNAC
5 
STAC 
STARD4-
AS1 
STAT4 STK35 STK39 STON2 STXBP4 SULT1C2 
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SUMF1 SUPT6H SVBP SVILP1 SYN3 SYNPO2 SYT6 
SYT9 SZT2 TAF9BP1 TBC1D19 TBC1D24 TBCA TCEANC 
TCP11 TEC TEKT5 TENM2 TENM3 TESC-AS1 TESPA1 
TEX13A TFEC THPO THSD7A THSD7B TIAM1 TIE1 
TIMM10B TM4SF5 TMED5 TMEM59L TMEM132B TMEM132D TMEM132E 
TMEM150C TMEM229B TMEM268 TMEM269 TMTC2 TNFRSF1A TNFRSF8 
TNFRSF10D TNFSF9 TNKS TNPO3 TNS1 TOB2 TOM1L1 
TOMM70 TOPORSLP
1 
TPGS1 TPGS2 TPP2 TPTE2 TRAF2 
TRAPPC9 TRHDE TRIB3 TRIM9 TRIM66 TRIP4 TRMT44 
TRPC4 TRPC6 TRPM2 TRPV4 TSHZ2 TSHZ3 TSNAX-
DISC1 
TSPAN11 TSPAN13 TTN TTN-AS1 TTYH2 TUSC3 TXNL4A 
U3 U8 UBE2E2 UBR1 UHRF1BP1
L 
UMAD1 UPP1 
UQCC1 USH1C USP5 USP43 UTP18 UTRN VAT1L 
VCAM1 VEGFD VEPH1 VRK2 VWA8 VWC2 WASF1P1 
WBSCR17 WDFY4 WDR7 WDR33 WFDC1 WLS WTAPP1 
WWOX XRCC6 Y_RNA YAP1 YBX1P10 ZBTB7C ZBTB20 
ZBTB20-AS1 ZC3H4 ZCWPW2 ZDHHC23 ZEB1-AS1 ZFPM2 ZMIZ1-AS1 
ZNF3 ZNF285 ZNF365 ZNF385D ZNF501 ZNF534 ZNF595 
ZNF609 ZNF718 ZNF804A ZNF836 ZNF837 ZPBP  
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IV. Permutation results 
  Table.9 Permutation results of 4 most significant SNPs with very low MAF (<0.01) 
SNP CHR p-value 
(Cox) 
Minor allele frequency (MAF) / count Permutated 
 p -value 
rs192512830 X 7.89x10-10 10-3 / 11 2.38x10-5 
rs117319230 4 1.34x10-9 5.71x10-4 / 6 1.56x10-5 
rs148193623 2 4.48x10-8 10-3 / 11 1.34x10-5 
rs6915535 6 2.77 x10-8 7.52x10-4 / 8 4.69x10-6 
SNP: Single Nucleotide Polymorphism MAF: Minor Allele Frequency, CHR: Chromosome 
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V. Power analysis of GWSA 
The assumptions for the power analysis were the additive genetic model, proportional hazards 
ratio, biallelic variant in Hardy-Weinberg equilibrium. Power was estimated (Fig. 25) using 
survSNP R library: Power Calculations for SNP Studies with Censored Outcomes (Owzar, Li, 
Cox, & Jung, 2012).  The FS analysis had around 10,000 sample with 5,000 cases (0.5, the rate of 
event observation to all observations) and CC had approximately 5,000 all cases (event rate is 
~0.99).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.24 Power analysis. The green strip denotes sample size (1,000, 5,000 and 10,000) and the 
brown one event rate (0.5, 0.7 and 0.99), q denotes the allele frequency 
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So, the top left corner and the middle row of third column of the Fig.25 represent the FS and CC 
analysis respectively. The power analysis suggests that these two analyses are well-powered (> 
0.8) in variants with Genotype hazard ratio > 1.4 and MAF > 0.01. For variants with small hazard 
ratio, the power of two analyses is steeply reduced below 80% for rarer variants. 
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VI. Remaining Gene Enrichment (g:GOSt) Results 
The first group of figures are the graphical outputs of gene list queries of the FS analysis. All 
the gene list queries per term are the same within each two Cox PH Analyses. This means each 
analysis has its own gene list query. These two gene lists can be found in Appendices section at 
the end of the thesis. 
 
Figure.25 g:GOSt results for Biological Process GO terms in CC analysis. 
The Biological Process GO term was the only option selected as the gene set enrichment 
term on the options panel. The far-left of the same figure has the first column as the GO category. 
The second column designates the term names, which are in hierarchical order. The far right-hand 
side is the color-coded matrix of gene annotations with column heads as gene names. (Fig.22 
explains each annotation). 
The Biological Process  GO category had enriched GO terms in the query gene list of CC 
analysis (Fig.24). Plasma membrane bounded cell projection organization (GO:0120036, q = 
4.59x10-5), dendrite development (GO:0016358, q = 7.08x10-5), and homophilic cell adhesion via 
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Figure 26 g:GOSt results for Cellular component in FS analysis. 
 
plasma membrane adhesion molecules (GO:0007156, q = 5.67x10-5) were the top three significant 
GO terms found as enriched in the CC query gene list.  
 
 
 
 
 
 
 
 
 
 
 
In Fig.26, cell periphery GO term (GO:71944) is indicated as the most significant (q = 
6.55x10-5) term among Cellular component GO category. The FS analysis GO term query has top 
significant loci mostly computationally (in silico) annotated genes. It also shows that there are 
significant gene enrichments in synapse (GO:0045202, q = 1.63x10-3) and neuron part 
(GO:0097458, q = 1.13x10-4) 
The most significant (q = 5.01x10-4) GO term is substrate specific transporter activity 
(GO:00022892) among other terms in the Molecular Function GO category as shown in Fig.27. 
As a subgroup of this category, ion transmembrane activity (GO:0015075) has a moderate gene 
set enrichment (q = 2.54x10-2).  
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Figure 27 g:GOSt results for Molecular Function GO term in FS analysis. 
Figure 28 g:GOSt results for KEGG pathways in FS analysis. 
Figure.29 g:GOSt results for Reactome pathway in FS analysis. 
 
 
 
 
 
 
 
 
 
  
  
The most significant pathway for FS analysis in KEGG pathway database is Choline 
metabolism in cancer (KEGG:05231, q = 2.36x10-2) as shown in Fig.28.  
 
 
 
  
Neuronal system (REAC:112316, q = 4.76x10-3) was the most significantly enriched Reactome 
gene set in the query gene list of the FS analysis as shown in Fig.29.  
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Figure.30 g:GOSt results for Cellular Component GO terms in CC analysis. 
Figure.31 g:GOSt results for Molecular Function GO term in CC analysis. 
 
 
 
 
 
 
 
Another broad category of Gene Ontology is Cellular Component (Fig.30). In this GO 
category, we found sixteen GO terms are significantly enriched in our query gene list based on 
results in CC analysis. Top two significant GO terms are Neuron part (GO:0097458, q = 2.02x10-
5) and Synapse (GO:0045202, q = 1.33x10-5). 
 
 
 
Molecular Function term called calcium ion binding (GO:0005509) shows a significant 
enrichment (q = 5.38x10-3) in the query gene list of CC analysis (Fig.31). 
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Figure.32 g:GOSt results for KEGG pathway in CC analysis. 
Figure.33 g:GOSt results for Reactome pathway in CC analysis. 
 
 
 
 
 
 
 
The gene enrichment results for KEGG pathways yield Glutamergic synapse 
(KEGG:04724, q = 2.82x10-4) and Circadian entrainment (KEGG:04713, q = 2.33x10-4) as 
statistically significant signals in CC analysis (Fig.32). 
Reactome pathway terms Nitric oxide stimulates guanylate cyclase (REAC: 392154, q = 
5x10-2) and Neuronal system (REAC:112316, q = 3.21x10-2) are the only two nominally 
significant findings from g:GOSt query of gene list of CC analysis (Fig.33).  
 In all gene set enrichment analysis from the main text, the only reported results were with 
q≤ 0.05 after Bonferroni correction. Effective domain size for GO is 18,971. Based on this 
number, g:GOSt accepts P < 6.58x10-6 as signal of significant enrichment after Bonferroni’s 
correction. On the other hand, the significance threshold for Benjamini-Hochberg FDR is P = 
6.28x10-3 for GO gene set enrichment. Table.10 is the counterpart of summary results table 
(Table.5) which adds FDR q-values for each GO term. FDR adjustments enhances the significance 
of the signals. 
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VII. Sensitivity analysis of gene set enrichment results 
When interpreting the GO term gene set enrichment results, it should be noted that the 
queries used the electronic annotations. This means that the results were based on in silico gene 
annotations. If you avoid using electronically annotated genes in gene set enrichment of g:GOSt, 
this would result in non-significant enrichments in some of the terms. The repeated g:GOSt queries 
with adding option “No electronic GO annotations” had the following results.  
For FS analysis, the only GO terms remain significant are cell periphery (Cellular 
Component, GO:0071944, q =3.84.91x10-4) and substrate specific transporter activity (Molecular 
Function, GO:0022892, q = 1.91x10-4). Also, axon guidance (Biological Process, GO:0007411, q 
= 1.91x10-2) came out as significantly enriched in FS analysis. This is somewhat different than the 
primary results for FS analysis on gene list query for GO term category Biological Process. 
For CC analysis, GO terms remain significant are neuron part (Cellular Component, 
GO:0097456, q = 3.89x10-4), lipid transporter activity (Molecular Function, GO:0005319, q = 
6.27x10-3) and regulation of neuron differentiation (Biological Process, GO:0045664, q = 5.15x10-
4). 
  
